1
|
Ru D, Li J, Xie O, Peng L, Jiang H, Qiu R. Explainable artificial intelligence based on feature optimization for age at onset prediction of spinocerebellar ataxia type 3. Front Neuroinform 2022; 16:978630. [PMID: 36110986 PMCID: PMC9468717 DOI: 10.3389/fninf.2022.978630] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2022] [Accepted: 08/09/2022] [Indexed: 11/13/2022] Open
Abstract
Existing treatments can only delay the progression of spinocerebellar ataxia type 3/Machado-Joseph disease (SCA3/MJD) after onset, so the prediction of the age at onset (AAO) can facilitate early intervention and follow-up to improve treatment efficacy. The objective of this study was to develop an explainable artificial intelligence (XAI) based on feature optimization to provide an interpretable and more accurate AAO prediction. A total of 1,008 affected SCA3/MJD subjects from mainland China were analyzed. The expanded cytosine-adenine-guanine (CAG) trinucleotide repeats of 10 polyQ-related genes were genotyped and included in related models as potential AAO modifiers. The performance of 4 feature optimization methods and 10 machine learning (ML) algorithms were compared, followed by building the XAI based on the SHapley Additive exPlanations (SHAP). The model constructed with an artificial neural network (ANN) and feature optimization of Crossing-Correlation-StepSVM performed best and achieved a coefficient of determination (R2) of 0.653 and mean absolute error (MAE), root mean square error (RMSE), and median absolute error (MedianAE) of 4.544, 6.090, and 3.236 years, respectively. The XAI explained the predicted results, which suggests that the factors affecting the AAO were complex and associated with gene interactions. An XAI based on feature optimization can improve the accuracy of AAO prediction and provide interpretable and personalized prediction.
Collapse
Affiliation(s)
- Danlei Ru
- School of Computer Science and Engineering, Central South University, Changsha, Hunan, China
| | - Jinchen Li
- National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, China
- Center for Medical Genetics and Hunan Key Laboratory of Medical Genetics, School of Life Sciences, Central South University, Changsha, Hunan, China
- Department of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan, China
| | - Ouyi Xie
- School of Computer Science and Engineering, Central South University, Changsha, Hunan, China
| | - Linliu Peng
- Department of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan, China
| | - Hong Jiang
- National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, China
- Department of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan, China
- School of Basic Medical Science, Central South University, Changsha, Hunan, China
- Key Laboratory of Hunan Province in Neurodegenerative Disorders, Central South University, Changsha, Hunan, China
- Hunan International Scientific and Technological Cooperation Base of Neurodegenerative and Neurogenetic Diseases, Changsha, China
| | - Rong Qiu
- School of Computer Science and Engineering, Central South University, Changsha, Hunan, China
- *Correspondence: Rong Qiu
| |
Collapse
|
2
|
Peng Y, Peng L, Chen Z, Peng H, Wang P, Zhang Y, Li Y, Wang C, Shi Y, Hou X, Long Z, Yuan H, Wan N, Wan L, Xu K, Lei L, Wang S, He L, Xie Y, Gong Y, Deng Q, Zou G, Tang Z, Shen L, Xia K, Qiu R, Klockgether T, Tang B, Jiang H. The Natural History of Spinocerebellar Ataxia Type 3 in Mainland China: A 2-Year Cohort Study. Front Aging Neurosci 2022; 14:917126. [PMID: 35865750 PMCID: PMC9294347 DOI: 10.3389/fnagi.2022.917126] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/10/2022] [Accepted: 06/13/2022] [Indexed: 11/21/2022] Open
Abstract
Objective The natural history of spinocerebellar ataxia type 3 (SCA3) has been reported in several populations and shows heterogeneity in progression rate and affecting factors. However, it remains unexplored in the population of Mainland China. This study aimed to identify the disease progression rate and its potential affecting factors in patients with SCA3 in Mainland China. Participants and Methods We enrolled patients with genetically confirmed SCA3 in Mainland China. Patients were seen at three visits, i.e., baseline, 1 year, and 2 years. The primary outcome was the Scale for the Assessment and Rating of Ataxia (SARA), and the secondary outcomes were the Inventory of Non-Ataxia Signs (INAS) as well as the SCA Functional Index (SCAFI). Results Between 1 October 2015, and 30 September 2016, we enrolled 263 patients with SCA3. We analyzed 247 patients with at least one follow-up visit. The annual progression rate of SARA was 1.49 points per year (SE 0.08, 95% confidence interval [CI] 1.33–1.65, p < 0.0001). The annual progression rates of INAS and SCAFI were 0.56 points per year (SE 0.05, 95% CI 0.47–0.66, p < 0.001) and −0.30 points per year (SE 0.01, 95% CI −0.33∼-0.28, p < 0.001), respectively. Faster progression in SARA was associated with longer length of the expanded allele of ATXN3 (p < 0.0001); faster progression in INAS was associated with lower INAS at baseline (p < 0.0001); faster decline in SCAFI was associated with shorter length of the normal allele of ATXN3 (p = 0.036) and higher SCAFI at baseline (p < 0.0001). Conclusion Our results provide quantitative data on the disease progression of patients with SCA3 in Mainland China and its corresponding affecting factors, which could facilitate the sample size calculation and patient stratification in future clinical trials. Trial Registration This study was registered with Chictr.org on 15 September 2015, number ChiCTR-OOC-15007124.
Collapse
Affiliation(s)
- Yun Peng
- Department of Neurology, Xiangya Hospital, Central South University, Changsha, China
| | - Linliu Peng
- Department of Neurology, Xiangya Hospital, Central South University, Changsha, China
| | - Zhao Chen
- Department of Neurology, Xiangya Hospital, Central South University, Changsha, China
| | - Huirong Peng
- Department of Neurology, Xiangya Hospital, Central South University, Changsha, China
| | - Puzhi Wang
- Department of Neurology, Xiangya Hospital, Central South University, Changsha, China
| | - Youming Zhang
- Department of Radiology, Xiangya Hospital, Central South University, Changsha, China
| | - Yangping Li
- Department of Human Genetics, Emory University School of Medicine, Atlanta, GA, United States
| | - Chunrong Wang
- Department of Pathology, Xiangya Hospital, Central South University, Changsha, China
| | - Yuting Shi
- Department of Neurology, Xiangya Hospital, Central South University, Changsha, China
| | - Xuan Hou
- Department of Neurology, Xiangya Hospital, Central South University, Changsha, China
| | - Zhe Long
- Department of Neurology, The Second Xiangya Hospital, Central South University, Changsha, China
| | - Hongyu Yuan
- Department of Neurology, Xiangya Hospital, Central South University, Changsha, China
| | - Na Wan
- Department of Neurology, Xiangya Hospital, Central South University, Changsha, China
| | - Linlin Wan
- Department of Neurology, Xiangya Hospital, Central South University, Changsha, China
| | - Keqin Xu
- Department of Neurology, Xiangya Hospital, Central South University, Changsha, China
| | - Lijing Lei
- Department of Neurology, Xiangya Hospital, Central South University, Changsha, China
| | - Shang Wang
- Department of Neurology, Xiangya Hospital, Central South University, Changsha, China
| | - Lang He
- Department of Neurology, Xiangya Hospital, Central South University, Changsha, China
| | - Yue Xie
- Department of Neurology, Xiangya Hospital, Central South University, Changsha, China
| | - Yiqing Gong
- Department of Neurology, Xiangya Hospital, Central South University, Changsha, China
| | - Qi Deng
- Department of Neurology, Xiangya Hospital, Central South University, Changsha, China
| | - Guangdong Zou
- Department of Neurology, Xiangya Hospital, Central South University, Changsha, China
| | - Zhichao Tang
- Department of Neurology, Xiangya Hospital, Central South University, Changsha, China
| | - Lu Shen
- Department of Neurology, Xiangya Hospital, Central South University, Changsha, China
- Laboratory of Medical Genetics, Central South University, Changsha, Hunan, China
- National Clinical Research Center for Geriatric Diseases, Xiangya Hospital, Central South University, Changsha, China
- Key Laboratory of Hunan Province in Neurodegenerative Disorders, Central South University, Changsha, China
- Hunan International Scientific and Technological Cooperation Base of Neurodegenerative and Neurogenetic Diseases, Changsha, China
| | - Kun Xia
- Laboratory of Medical Genetics, Central South University, Changsha, Hunan, China
| | - Rong Qiu
- School of Computer Science and Engineering, Central South University, Changsha, China
| | - Thomas Klockgether
- Department of Neurology, University of Bonn, Bonn, Germany
- German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany
| | - Beisha Tang
- Department of Neurology, Xiangya Hospital, Central South University, Changsha, China
- Laboratory of Medical Genetics, Central South University, Changsha, Hunan, China
- National Clinical Research Center for Geriatric Diseases, Xiangya Hospital, Central South University, Changsha, China
- Key Laboratory of Hunan Province in Neurodegenerative Disorders, Central South University, Changsha, China
- Hunan International Scientific and Technological Cooperation Base of Neurodegenerative and Neurogenetic Diseases, Changsha, China
| | - Hong Jiang
- Department of Neurology, Xiangya Hospital, Central South University, Changsha, China
- Laboratory of Medical Genetics, Central South University, Changsha, Hunan, China
- National Clinical Research Center for Geriatric Diseases, Xiangya Hospital, Central South University, Changsha, China
- Key Laboratory of Hunan Province in Neurodegenerative Disorders, Central South University, Changsha, China
- Hunan International Scientific and Technological Cooperation Base of Neurodegenerative and Neurogenetic Diseases, Changsha, China
- *Correspondence: Hong Jiang,
| |
Collapse
|
3
|
Ding D, Chen Z, Wang C, Tang X, Zhang L, Fang Q, Qiu R, Jiang H. A Variant in Genes of the NPY System as Modifier Factor of Machado-Joseph Disease in the Chinese Population. Front Aging Neurosci 2022; 14:822657. [PMID: 35185528 PMCID: PMC8851415 DOI: 10.3389/fnagi.2022.822657] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/26/2021] [Accepted: 01/11/2022] [Indexed: 11/13/2022] Open
Abstract
Recently, NPY overexpression has been proposed to alleviate motor deficits and neuropathy in Machado-Joseph disease (MJD) mouse models, indicating its neuroprotective role in the pathogenesis of MJD. We aimed to evaluate the association between SNPs in NPY and its receptors and the susceptibility of MJD in the Chinese population. Moreover, we investigated whether these SNPs modulate the age at onset (AO) of MJD. In total, 527 MJD patients and 487 healthy controls were enrolled in the study, and four specific selected SNPs (rs16139, rs3037354, rs2234759, and rs11100494) in NPY and its receptor genes were genotyped. In this study, the genotypic frequency using the dominant model and the allelic distribution of rs11100494 in NPY5R revealed a significant difference between the MJD and control group during the first-stage analysis (P = 0.048 and P = 0.024, respectively). After we expanded the sample size, significant differences were observed between the two groups using the dominant model in genotypic and allelic distribution (P = 0.034, P = 0.046, and P = 0.016, respectively). No significant differences in genotypic and allelic distribution were found between the MJD and control groups for the other three SNPs. All selected SNPs had no significant effect on the AO of MJD. The association of rs11100494 in the NPY5R gene and susceptibility of MJD suggested that the NPY system might be implicated in the pathogenesis of MJD. Our study demonstrated the existence of other genetic modifiers in MJD, along with CAG expansion and known genetic modifier factors, which might lead to a better understanding of MJD pathogenesis.
Collapse
Affiliation(s)
- Dongxue Ding
- Department of Neurology, The First Affiliated Hospital of Soochow University, Suzhou, China
| | - Zhao Chen
- Department of Neurology, Xiangya Hospital, Central South University, Changsha, China
| | - Chunrong Wang
- Department of Pathology, Xiangya Hospital, Central South University, Changsha, China
| | - Xiang Tang
- Department of Neurology, The First Affiliated Hospital of Soochow University, Suzhou, China
| | - Lulu Zhang
- Department of Neurology, The First Affiliated Hospital of Soochow University, Suzhou, China
| | - Qi Fang
- Department of Neurology, The First Affiliated Hospital of Soochow University, Suzhou, China
| | - Rong Qiu
- School of Information Science and Engineering, Central South University, Changsha, China
| | - Hong Jiang
- Department of Neurology, Xiangya Hospital, Central South University, Changsha, China
- Key Laboratory of Hunan Province in Neurodegenerative Disorders, Central South University, Changsha, China
- National Clinical Research Center for Geriatric Diseases, Central South University, Changsha, China
- Laboratory of Medical Genetics, Central South University, Changsha, China
- School of Basic Medical Science, Central South University, Changsha, China
- Hunan International Scientific and Technological Cooperation Base of Neurodegenerative and Neurogenetic Diseases, Changsha, China
- *Correspondence: Hong Jiang,
| |
Collapse
|
4
|
Ogura M, Toyoda Y, Sakiyama M, Kawamura Y, Nakayama A, Yamanashi Y, Takada T, Shimizu S, Higashino T, Nakajima M, Naito M, Hishida A, Kawai S, Okada R, Sasaki M, Ayaori M, Suzuki H, Takata K, Ikewaki K, Harada-Shiba M, Shinomiya N, Matsuo H. Increase of serum uric acid levels associated with APOE ε2 haplotype: a clinico-genetic investigation and in vivo approach. Hum Cell 2021; 34:1727-1733. [PMID: 34532841 PMCID: PMC8490264 DOI: 10.1007/s13577-021-00609-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2021] [Accepted: 09/02/2021] [Indexed: 10/30/2022]
Abstract
Elevated serum uric acid (SUA)-hyperuricemia-is caused by overproduction of urate or by its decreased renal and/or intestinal excretion. This disease, which is increasing in prevalence worldwide, is associated with both gout and metabolic diseases. Several studies have reported relationships between apolipoprotein E (APOE) haplotypes and SUA levels in humans; however, their results remain inconsistent. This prompted us to investigate the relationship between APOE polymorphisms and SUA levels. Our subjects were 5,272 Japanese men, premenopausal women, and postmenopausal women. Multiple linear regression analyses revealed the ε2 haplotype of APOE to be independently associated with higher SUA in men (N = 1,726) and postmenopausal women (N = 1,753), but not in premenopausal women (N = 1,793). In contrast, the ε4 haplotype was little related to SUA levels in each group. Moreover, to examine the effect of Apoe deficiency on SUA levels, we conducted animal experiments using Apoe knockout mice, which mimics ε2/ε2 carriers. We found that SUA levels in Apoe knockout mice were significantly higher than those in wild-type mice, which is consistent with the SUA-raising effect of the ε2 haplotype observed in our clinico-genetic analyses. Further analyses suggested that renal rather than intestinal underexcretion of urate could be involved in Apoe deficiency-related SUA increase. In conclusion, we successfully demonstrated that the ε2 haplotype, but not the ε4 haplotype, increases SUA levels. These findings will improve our understanding of genetic factors affecting SUA levels.
Collapse
Affiliation(s)
- Masatsune Ogura
- Department of Metabolism and Endocrinology, Eastern Chiba Medical Center, 3-6-2 Okayamadai, Togane, Chiba, 283-8686, Japan.
- Department of General Medical Science, Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba, Chiba, 260-8670, Japan.
- Department of Molecular Innovation in Lipidology, National Cerebral and Cardiovascular Center Research Institute, 6-1 Kishibe-shinmachi, Suita, Osaka, 564-8565, Japan.
| | - Yu Toyoda
- Department of Integrative Physiology and Bio-Nano Medicine, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama, 359-8513, Japan
| | - Masayuki Sakiyama
- Department of Integrative Physiology and Bio-Nano Medicine, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama, 359-8513, Japan
- Department of Dermatology, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama, 359-8513, Japan
| | - Yusuke Kawamura
- Department of Integrative Physiology and Bio-Nano Medicine, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama, 359-8513, Japan
| | - Akiyoshi Nakayama
- Department of Integrative Physiology and Bio-Nano Medicine, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama, 359-8513, Japan
| | - Yoshihide Yamanashi
- Department of Pharmacy, Faculty of Medicine, The University of Tokyo Hospital, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan
| | - Tappei Takada
- Department of Pharmacy, Faculty of Medicine, The University of Tokyo Hospital, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan
| | - Seiko Shimizu
- Department of Integrative Physiology and Bio-Nano Medicine, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama, 359-8513, Japan
| | - Toshihide Higashino
- Department of Integrative Physiology and Bio-Nano Medicine, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama, 359-8513, Japan
| | - Mayuko Nakajima
- Department of Integrative Physiology and Bio-Nano Medicine, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama, 359-8513, Japan
| | - Mariko Naito
- Department of Preventive Medicine, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, Aichi, 466-8550, Japan
- Department of Oral Epidemiology, Hiroshima University Graduate School of Biomedical and Health Sciences, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8553, Japan
| | - Asahi Hishida
- Department of Preventive Medicine, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, Aichi, 466-8550, Japan
| | - Sayo Kawai
- Department of Preventive Medicine, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, Aichi, 466-8550, Japan
- Department of Public Health, Aichi Medical University School of Medicine, 1-1 Yazako-karimata, Nagakute, Aichi, 480-1195, Japan
| | - Rieko Okada
- Department of Preventive Medicine, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, Aichi, 466-8550, Japan
| | - Makoto Sasaki
- Division of Anti-Aging and Vascular Medicine, Department of Internal Medicine, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama, 359-8513, Japan
| | - Makoto Ayaori
- Division of Anti-Aging and Vascular Medicine, Department of Internal Medicine, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama, 359-8513, Japan
| | - Hiroshi Suzuki
- Department of Pharmacy, Faculty of Medicine, The University of Tokyo Hospital, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan
| | - Koki Takata
- Takata Clinic, 10-15 Wakakusa-cho, Higashi-ku, Hiroshima, Hiroshima, 732-0053, Japan
| | - Katsunori Ikewaki
- Division of Anti-Aging and Vascular Medicine, Department of Internal Medicine, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama, 359-8513, Japan
| | - Mariko Harada-Shiba
- Department of Molecular Innovation in Lipidology, National Cerebral and Cardiovascular Center Research Institute, 6-1 Kishibe-shinmachi, Suita, Osaka, 564-8565, Japan
| | - Nariyoshi Shinomiya
- Department of Integrative Physiology and Bio-Nano Medicine, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama, 359-8513, Japan
| | - Hirotaka Matsuo
- Department of Integrative Physiology and Bio-Nano Medicine, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama, 359-8513, Japan.
| |
Collapse
|
5
|
Peng L, Chen Z, Long Z, Liu M, Lei L, Wang C, Peng H, Shi Y, Peng Y, Deng Q, Wang S, Zou G, Wan L, Yuan H, He L, Xie Y, Tang Z, Wan N, Gong Y, Hou X, Shen L, Xia K, Li J, Chen C, Qiu R, Klockgether T, Tang B, Jiang H. New Model for Estimation of the Age at Onset in Spinocerebellar Ataxia Type 3. Neurology 2021; 96:e2885-e2895. [PMID: 33893204 DOI: 10.1212/wnl.0000000000012068] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2020] [Accepted: 03/11/2021] [Indexed: 12/11/2022] Open
Abstract
OBJECTIVES The aim of this study was to develop an appropriate parametric survival model to predict patient's age at onset (AAO) for spinocerebellar ataxia type 3/Machado-Joseph disease (SCA3/MJD) populations from mainland China. METHODS We compared the efficiency and performance of 6 parametric survival analysis methods (exponential, weibull, log-gaussian, gaussian, log-logistic, and logistic) based on cytosine-adenine-guanine (CAG) repeat length at ATXN3 to predict the probability of AAO in the largest cohort of patients with SCA3/MJD. A set of evaluation criteria, including -2 log-likelihood statistic, Akaike information criterion (AIC), bayesian information criterion (BIC), Nagelkerke R-squared (Nagelkerke R^2), and Cox-Snell residual plot, were used to identify the best model. RESULTS Among these 6 parametric survival models, the logistic model had the lowest -2 log-likelihood (6,560.12), AIC (6,566.12), and BIC (6,566.14) and the highest value of Nagelkerke R^2 (0.54), with the closest graph to the bisector Cox-Snell residual graph. Therefore, the logistic survival model was the best fit to the studied data. Using the optimal logistic survival model, we indicated the age-specific probability distribution of AAO according to the CAG repeat size and current age. CONCLUSIONS We first demonstrated that the logistic survival model provided the best fit for AAO prediction in patients with SCA3/MJD from mainland China. This optimal model can be valuable in clinical and research. However, the rigorous clinical testing and practice of other independent cohorts are needed for its clinical application. A unified model across multiethnic cohorts is worth further exploration by identifying regional differences and significant modifiers in AAO determination.
Collapse
Affiliation(s)
- Linliu Peng
- From the Department of Neurology (L.P., Z.C., M.L., L.L., H.P., Y.S., Y.P., Q.D., S.W., G.Z., L.W., H.Y., L.H., Y.X., Z.T., N.W., Y.G., X.H., L.S., J.L., B.T., H.J.), Department of Pathology (C.W.), National Clinical Research Center for Geriatric Disorders (Z.C., L.S., B.T., H.J.), Xiangya Hospital, Central South University; Department of Neurology (Z.L.), The Second Xiangya Hospital, Central South University; Key Laboratory of Hunan Province in Neurodegenerative Disorders (Z.C., L.S., J.L., B.T., H.J.), Center for Medical Genetics School of Life Sciences (K.X., J.L., C.C.), Hunan Key Laboratory of Medical Genetics (K.X., J.L., C.C.), School of Computer Science and Engineering (R.Q.), and School of Basic Medical Science (H.J.), Central South University, Changsha, Hunan, China; Department of Neurology (T.K.), University of Bonn; and German Center for Neurodegenerative Diseases (DZNE) (T.K.), Bonn, Germany
| | - Zhao Chen
- From the Department of Neurology (L.P., Z.C., M.L., L.L., H.P., Y.S., Y.P., Q.D., S.W., G.Z., L.W., H.Y., L.H., Y.X., Z.T., N.W., Y.G., X.H., L.S., J.L., B.T., H.J.), Department of Pathology (C.W.), National Clinical Research Center for Geriatric Disorders (Z.C., L.S., B.T., H.J.), Xiangya Hospital, Central South University; Department of Neurology (Z.L.), The Second Xiangya Hospital, Central South University; Key Laboratory of Hunan Province in Neurodegenerative Disorders (Z.C., L.S., J.L., B.T., H.J.), Center for Medical Genetics School of Life Sciences (K.X., J.L., C.C.), Hunan Key Laboratory of Medical Genetics (K.X., J.L., C.C.), School of Computer Science and Engineering (R.Q.), and School of Basic Medical Science (H.J.), Central South University, Changsha, Hunan, China; Department of Neurology (T.K.), University of Bonn; and German Center for Neurodegenerative Diseases (DZNE) (T.K.), Bonn, Germany
| | - Zhe Long
- From the Department of Neurology (L.P., Z.C., M.L., L.L., H.P., Y.S., Y.P., Q.D., S.W., G.Z., L.W., H.Y., L.H., Y.X., Z.T., N.W., Y.G., X.H., L.S., J.L., B.T., H.J.), Department of Pathology (C.W.), National Clinical Research Center for Geriatric Disorders (Z.C., L.S., B.T., H.J.), Xiangya Hospital, Central South University; Department of Neurology (Z.L.), The Second Xiangya Hospital, Central South University; Key Laboratory of Hunan Province in Neurodegenerative Disorders (Z.C., L.S., J.L., B.T., H.J.), Center for Medical Genetics School of Life Sciences (K.X., J.L., C.C.), Hunan Key Laboratory of Medical Genetics (K.X., J.L., C.C.), School of Computer Science and Engineering (R.Q.), and School of Basic Medical Science (H.J.), Central South University, Changsha, Hunan, China; Department of Neurology (T.K.), University of Bonn; and German Center for Neurodegenerative Diseases (DZNE) (T.K.), Bonn, Germany
| | - Mingjie Liu
- From the Department of Neurology (L.P., Z.C., M.L., L.L., H.P., Y.S., Y.P., Q.D., S.W., G.Z., L.W., H.Y., L.H., Y.X., Z.T., N.W., Y.G., X.H., L.S., J.L., B.T., H.J.), Department of Pathology (C.W.), National Clinical Research Center for Geriatric Disorders (Z.C., L.S., B.T., H.J.), Xiangya Hospital, Central South University; Department of Neurology (Z.L.), The Second Xiangya Hospital, Central South University; Key Laboratory of Hunan Province in Neurodegenerative Disorders (Z.C., L.S., J.L., B.T., H.J.), Center for Medical Genetics School of Life Sciences (K.X., J.L., C.C.), Hunan Key Laboratory of Medical Genetics (K.X., J.L., C.C.), School of Computer Science and Engineering (R.Q.), and School of Basic Medical Science (H.J.), Central South University, Changsha, Hunan, China; Department of Neurology (T.K.), University of Bonn; and German Center for Neurodegenerative Diseases (DZNE) (T.K.), Bonn, Germany
| | - Lijing Lei
- From the Department of Neurology (L.P., Z.C., M.L., L.L., H.P., Y.S., Y.P., Q.D., S.W., G.Z., L.W., H.Y., L.H., Y.X., Z.T., N.W., Y.G., X.H., L.S., J.L., B.T., H.J.), Department of Pathology (C.W.), National Clinical Research Center for Geriatric Disorders (Z.C., L.S., B.T., H.J.), Xiangya Hospital, Central South University; Department of Neurology (Z.L.), The Second Xiangya Hospital, Central South University; Key Laboratory of Hunan Province in Neurodegenerative Disorders (Z.C., L.S., J.L., B.T., H.J.), Center for Medical Genetics School of Life Sciences (K.X., J.L., C.C.), Hunan Key Laboratory of Medical Genetics (K.X., J.L., C.C.), School of Computer Science and Engineering (R.Q.), and School of Basic Medical Science (H.J.), Central South University, Changsha, Hunan, China; Department of Neurology (T.K.), University of Bonn; and German Center for Neurodegenerative Diseases (DZNE) (T.K.), Bonn, Germany
| | - Chunrong Wang
- From the Department of Neurology (L.P., Z.C., M.L., L.L., H.P., Y.S., Y.P., Q.D., S.W., G.Z., L.W., H.Y., L.H., Y.X., Z.T., N.W., Y.G., X.H., L.S., J.L., B.T., H.J.), Department of Pathology (C.W.), National Clinical Research Center for Geriatric Disorders (Z.C., L.S., B.T., H.J.), Xiangya Hospital, Central South University; Department of Neurology (Z.L.), The Second Xiangya Hospital, Central South University; Key Laboratory of Hunan Province in Neurodegenerative Disorders (Z.C., L.S., J.L., B.T., H.J.), Center for Medical Genetics School of Life Sciences (K.X., J.L., C.C.), Hunan Key Laboratory of Medical Genetics (K.X., J.L., C.C.), School of Computer Science and Engineering (R.Q.), and School of Basic Medical Science (H.J.), Central South University, Changsha, Hunan, China; Department of Neurology (T.K.), University of Bonn; and German Center for Neurodegenerative Diseases (DZNE) (T.K.), Bonn, Germany
| | - Huirong Peng
- From the Department of Neurology (L.P., Z.C., M.L., L.L., H.P., Y.S., Y.P., Q.D., S.W., G.Z., L.W., H.Y., L.H., Y.X., Z.T., N.W., Y.G., X.H., L.S., J.L., B.T., H.J.), Department of Pathology (C.W.), National Clinical Research Center for Geriatric Disorders (Z.C., L.S., B.T., H.J.), Xiangya Hospital, Central South University; Department of Neurology (Z.L.), The Second Xiangya Hospital, Central South University; Key Laboratory of Hunan Province in Neurodegenerative Disorders (Z.C., L.S., J.L., B.T., H.J.), Center for Medical Genetics School of Life Sciences (K.X., J.L., C.C.), Hunan Key Laboratory of Medical Genetics (K.X., J.L., C.C.), School of Computer Science and Engineering (R.Q.), and School of Basic Medical Science (H.J.), Central South University, Changsha, Hunan, China; Department of Neurology (T.K.), University of Bonn; and German Center for Neurodegenerative Diseases (DZNE) (T.K.), Bonn, Germany
| | - Yuting Shi
- From the Department of Neurology (L.P., Z.C., M.L., L.L., H.P., Y.S., Y.P., Q.D., S.W., G.Z., L.W., H.Y., L.H., Y.X., Z.T., N.W., Y.G., X.H., L.S., J.L., B.T., H.J.), Department of Pathology (C.W.), National Clinical Research Center for Geriatric Disorders (Z.C., L.S., B.T., H.J.), Xiangya Hospital, Central South University; Department of Neurology (Z.L.), The Second Xiangya Hospital, Central South University; Key Laboratory of Hunan Province in Neurodegenerative Disorders (Z.C., L.S., J.L., B.T., H.J.), Center for Medical Genetics School of Life Sciences (K.X., J.L., C.C.), Hunan Key Laboratory of Medical Genetics (K.X., J.L., C.C.), School of Computer Science and Engineering (R.Q.), and School of Basic Medical Science (H.J.), Central South University, Changsha, Hunan, China; Department of Neurology (T.K.), University of Bonn; and German Center for Neurodegenerative Diseases (DZNE) (T.K.), Bonn, Germany
| | - Yun Peng
- From the Department of Neurology (L.P., Z.C., M.L., L.L., H.P., Y.S., Y.P., Q.D., S.W., G.Z., L.W., H.Y., L.H., Y.X., Z.T., N.W., Y.G., X.H., L.S., J.L., B.T., H.J.), Department of Pathology (C.W.), National Clinical Research Center for Geriatric Disorders (Z.C., L.S., B.T., H.J.), Xiangya Hospital, Central South University; Department of Neurology (Z.L.), The Second Xiangya Hospital, Central South University; Key Laboratory of Hunan Province in Neurodegenerative Disorders (Z.C., L.S., J.L., B.T., H.J.), Center for Medical Genetics School of Life Sciences (K.X., J.L., C.C.), Hunan Key Laboratory of Medical Genetics (K.X., J.L., C.C.), School of Computer Science and Engineering (R.Q.), and School of Basic Medical Science (H.J.), Central South University, Changsha, Hunan, China; Department of Neurology (T.K.), University of Bonn; and German Center for Neurodegenerative Diseases (DZNE) (T.K.), Bonn, Germany
| | - Qi Deng
- From the Department of Neurology (L.P., Z.C., M.L., L.L., H.P., Y.S., Y.P., Q.D., S.W., G.Z., L.W., H.Y., L.H., Y.X., Z.T., N.W., Y.G., X.H., L.S., J.L., B.T., H.J.), Department of Pathology (C.W.), National Clinical Research Center for Geriatric Disorders (Z.C., L.S., B.T., H.J.), Xiangya Hospital, Central South University; Department of Neurology (Z.L.), The Second Xiangya Hospital, Central South University; Key Laboratory of Hunan Province in Neurodegenerative Disorders (Z.C., L.S., J.L., B.T., H.J.), Center for Medical Genetics School of Life Sciences (K.X., J.L., C.C.), Hunan Key Laboratory of Medical Genetics (K.X., J.L., C.C.), School of Computer Science and Engineering (R.Q.), and School of Basic Medical Science (H.J.), Central South University, Changsha, Hunan, China; Department of Neurology (T.K.), University of Bonn; and German Center for Neurodegenerative Diseases (DZNE) (T.K.), Bonn, Germany
| | - Shang Wang
- From the Department of Neurology (L.P., Z.C., M.L., L.L., H.P., Y.S., Y.P., Q.D., S.W., G.Z., L.W., H.Y., L.H., Y.X., Z.T., N.W., Y.G., X.H., L.S., J.L., B.T., H.J.), Department of Pathology (C.W.), National Clinical Research Center for Geriatric Disorders (Z.C., L.S., B.T., H.J.), Xiangya Hospital, Central South University; Department of Neurology (Z.L.), The Second Xiangya Hospital, Central South University; Key Laboratory of Hunan Province in Neurodegenerative Disorders (Z.C., L.S., J.L., B.T., H.J.), Center for Medical Genetics School of Life Sciences (K.X., J.L., C.C.), Hunan Key Laboratory of Medical Genetics (K.X., J.L., C.C.), School of Computer Science and Engineering (R.Q.), and School of Basic Medical Science (H.J.), Central South University, Changsha, Hunan, China; Department of Neurology (T.K.), University of Bonn; and German Center for Neurodegenerative Diseases (DZNE) (T.K.), Bonn, Germany
| | - Guangdong Zou
- From the Department of Neurology (L.P., Z.C., M.L., L.L., H.P., Y.S., Y.P., Q.D., S.W., G.Z., L.W., H.Y., L.H., Y.X., Z.T., N.W., Y.G., X.H., L.S., J.L., B.T., H.J.), Department of Pathology (C.W.), National Clinical Research Center for Geriatric Disorders (Z.C., L.S., B.T., H.J.), Xiangya Hospital, Central South University; Department of Neurology (Z.L.), The Second Xiangya Hospital, Central South University; Key Laboratory of Hunan Province in Neurodegenerative Disorders (Z.C., L.S., J.L., B.T., H.J.), Center for Medical Genetics School of Life Sciences (K.X., J.L., C.C.), Hunan Key Laboratory of Medical Genetics (K.X., J.L., C.C.), School of Computer Science and Engineering (R.Q.), and School of Basic Medical Science (H.J.), Central South University, Changsha, Hunan, China; Department of Neurology (T.K.), University of Bonn; and German Center for Neurodegenerative Diseases (DZNE) (T.K.), Bonn, Germany
| | - Linlin Wan
- From the Department of Neurology (L.P., Z.C., M.L., L.L., H.P., Y.S., Y.P., Q.D., S.W., G.Z., L.W., H.Y., L.H., Y.X., Z.T., N.W., Y.G., X.H., L.S., J.L., B.T., H.J.), Department of Pathology (C.W.), National Clinical Research Center for Geriatric Disorders (Z.C., L.S., B.T., H.J.), Xiangya Hospital, Central South University; Department of Neurology (Z.L.), The Second Xiangya Hospital, Central South University; Key Laboratory of Hunan Province in Neurodegenerative Disorders (Z.C., L.S., J.L., B.T., H.J.), Center for Medical Genetics School of Life Sciences (K.X., J.L., C.C.), Hunan Key Laboratory of Medical Genetics (K.X., J.L., C.C.), School of Computer Science and Engineering (R.Q.), and School of Basic Medical Science (H.J.), Central South University, Changsha, Hunan, China; Department of Neurology (T.K.), University of Bonn; and German Center for Neurodegenerative Diseases (DZNE) (T.K.), Bonn, Germany
| | - Hongyu Yuan
- From the Department of Neurology (L.P., Z.C., M.L., L.L., H.P., Y.S., Y.P., Q.D., S.W., G.Z., L.W., H.Y., L.H., Y.X., Z.T., N.W., Y.G., X.H., L.S., J.L., B.T., H.J.), Department of Pathology (C.W.), National Clinical Research Center for Geriatric Disorders (Z.C., L.S., B.T., H.J.), Xiangya Hospital, Central South University; Department of Neurology (Z.L.), The Second Xiangya Hospital, Central South University; Key Laboratory of Hunan Province in Neurodegenerative Disorders (Z.C., L.S., J.L., B.T., H.J.), Center for Medical Genetics School of Life Sciences (K.X., J.L., C.C.), Hunan Key Laboratory of Medical Genetics (K.X., J.L., C.C.), School of Computer Science and Engineering (R.Q.), and School of Basic Medical Science (H.J.), Central South University, Changsha, Hunan, China; Department of Neurology (T.K.), University of Bonn; and German Center for Neurodegenerative Diseases (DZNE) (T.K.), Bonn, Germany
| | - Lang He
- From the Department of Neurology (L.P., Z.C., M.L., L.L., H.P., Y.S., Y.P., Q.D., S.W., G.Z., L.W., H.Y., L.H., Y.X., Z.T., N.W., Y.G., X.H., L.S., J.L., B.T., H.J.), Department of Pathology (C.W.), National Clinical Research Center for Geriatric Disorders (Z.C., L.S., B.T., H.J.), Xiangya Hospital, Central South University; Department of Neurology (Z.L.), The Second Xiangya Hospital, Central South University; Key Laboratory of Hunan Province in Neurodegenerative Disorders (Z.C., L.S., J.L., B.T., H.J.), Center for Medical Genetics School of Life Sciences (K.X., J.L., C.C.), Hunan Key Laboratory of Medical Genetics (K.X., J.L., C.C.), School of Computer Science and Engineering (R.Q.), and School of Basic Medical Science (H.J.), Central South University, Changsha, Hunan, China; Department of Neurology (T.K.), University of Bonn; and German Center for Neurodegenerative Diseases (DZNE) (T.K.), Bonn, Germany
| | - Yue Xie
- From the Department of Neurology (L.P., Z.C., M.L., L.L., H.P., Y.S., Y.P., Q.D., S.W., G.Z., L.W., H.Y., L.H., Y.X., Z.T., N.W., Y.G., X.H., L.S., J.L., B.T., H.J.), Department of Pathology (C.W.), National Clinical Research Center for Geriatric Disorders (Z.C., L.S., B.T., H.J.), Xiangya Hospital, Central South University; Department of Neurology (Z.L.), The Second Xiangya Hospital, Central South University; Key Laboratory of Hunan Province in Neurodegenerative Disorders (Z.C., L.S., J.L., B.T., H.J.), Center for Medical Genetics School of Life Sciences (K.X., J.L., C.C.), Hunan Key Laboratory of Medical Genetics (K.X., J.L., C.C.), School of Computer Science and Engineering (R.Q.), and School of Basic Medical Science (H.J.), Central South University, Changsha, Hunan, China; Department of Neurology (T.K.), University of Bonn; and German Center for Neurodegenerative Diseases (DZNE) (T.K.), Bonn, Germany
| | - Zhichao Tang
- From the Department of Neurology (L.P., Z.C., M.L., L.L., H.P., Y.S., Y.P., Q.D., S.W., G.Z., L.W., H.Y., L.H., Y.X., Z.T., N.W., Y.G., X.H., L.S., J.L., B.T., H.J.), Department of Pathology (C.W.), National Clinical Research Center for Geriatric Disorders (Z.C., L.S., B.T., H.J.), Xiangya Hospital, Central South University; Department of Neurology (Z.L.), The Second Xiangya Hospital, Central South University; Key Laboratory of Hunan Province in Neurodegenerative Disorders (Z.C., L.S., J.L., B.T., H.J.), Center for Medical Genetics School of Life Sciences (K.X., J.L., C.C.), Hunan Key Laboratory of Medical Genetics (K.X., J.L., C.C.), School of Computer Science and Engineering (R.Q.), and School of Basic Medical Science (H.J.), Central South University, Changsha, Hunan, China; Department of Neurology (T.K.), University of Bonn; and German Center for Neurodegenerative Diseases (DZNE) (T.K.), Bonn, Germany
| | - Na Wan
- From the Department of Neurology (L.P., Z.C., M.L., L.L., H.P., Y.S., Y.P., Q.D., S.W., G.Z., L.W., H.Y., L.H., Y.X., Z.T., N.W., Y.G., X.H., L.S., J.L., B.T., H.J.), Department of Pathology (C.W.), National Clinical Research Center for Geriatric Disorders (Z.C., L.S., B.T., H.J.), Xiangya Hospital, Central South University; Department of Neurology (Z.L.), The Second Xiangya Hospital, Central South University; Key Laboratory of Hunan Province in Neurodegenerative Disorders (Z.C., L.S., J.L., B.T., H.J.), Center for Medical Genetics School of Life Sciences (K.X., J.L., C.C.), Hunan Key Laboratory of Medical Genetics (K.X., J.L., C.C.), School of Computer Science and Engineering (R.Q.), and School of Basic Medical Science (H.J.), Central South University, Changsha, Hunan, China; Department of Neurology (T.K.), University of Bonn; and German Center for Neurodegenerative Diseases (DZNE) (T.K.), Bonn, Germany
| | - Yiqing Gong
- From the Department of Neurology (L.P., Z.C., M.L., L.L., H.P., Y.S., Y.P., Q.D., S.W., G.Z., L.W., H.Y., L.H., Y.X., Z.T., N.W., Y.G., X.H., L.S., J.L., B.T., H.J.), Department of Pathology (C.W.), National Clinical Research Center for Geriatric Disorders (Z.C., L.S., B.T., H.J.), Xiangya Hospital, Central South University; Department of Neurology (Z.L.), The Second Xiangya Hospital, Central South University; Key Laboratory of Hunan Province in Neurodegenerative Disorders (Z.C., L.S., J.L., B.T., H.J.), Center for Medical Genetics School of Life Sciences (K.X., J.L., C.C.), Hunan Key Laboratory of Medical Genetics (K.X., J.L., C.C.), School of Computer Science and Engineering (R.Q.), and School of Basic Medical Science (H.J.), Central South University, Changsha, Hunan, China; Department of Neurology (T.K.), University of Bonn; and German Center for Neurodegenerative Diseases (DZNE) (T.K.), Bonn, Germany
| | - Xuan Hou
- From the Department of Neurology (L.P., Z.C., M.L., L.L., H.P., Y.S., Y.P., Q.D., S.W., G.Z., L.W., H.Y., L.H., Y.X., Z.T., N.W., Y.G., X.H., L.S., J.L., B.T., H.J.), Department of Pathology (C.W.), National Clinical Research Center for Geriatric Disorders (Z.C., L.S., B.T., H.J.), Xiangya Hospital, Central South University; Department of Neurology (Z.L.), The Second Xiangya Hospital, Central South University; Key Laboratory of Hunan Province in Neurodegenerative Disorders (Z.C., L.S., J.L., B.T., H.J.), Center for Medical Genetics School of Life Sciences (K.X., J.L., C.C.), Hunan Key Laboratory of Medical Genetics (K.X., J.L., C.C.), School of Computer Science and Engineering (R.Q.), and School of Basic Medical Science (H.J.), Central South University, Changsha, Hunan, China; Department of Neurology (T.K.), University of Bonn; and German Center for Neurodegenerative Diseases (DZNE) (T.K.), Bonn, Germany
| | - Lu Shen
- From the Department of Neurology (L.P., Z.C., M.L., L.L., H.P., Y.S., Y.P., Q.D., S.W., G.Z., L.W., H.Y., L.H., Y.X., Z.T., N.W., Y.G., X.H., L.S., J.L., B.T., H.J.), Department of Pathology (C.W.), National Clinical Research Center for Geriatric Disorders (Z.C., L.S., B.T., H.J.), Xiangya Hospital, Central South University; Department of Neurology (Z.L.), The Second Xiangya Hospital, Central South University; Key Laboratory of Hunan Province in Neurodegenerative Disorders (Z.C., L.S., J.L., B.T., H.J.), Center for Medical Genetics School of Life Sciences (K.X., J.L., C.C.), Hunan Key Laboratory of Medical Genetics (K.X., J.L., C.C.), School of Computer Science and Engineering (R.Q.), and School of Basic Medical Science (H.J.), Central South University, Changsha, Hunan, China; Department of Neurology (T.K.), University of Bonn; and German Center for Neurodegenerative Diseases (DZNE) (T.K.), Bonn, Germany
| | - Kun Xia
- From the Department of Neurology (L.P., Z.C., M.L., L.L., H.P., Y.S., Y.P., Q.D., S.W., G.Z., L.W., H.Y., L.H., Y.X., Z.T., N.W., Y.G., X.H., L.S., J.L., B.T., H.J.), Department of Pathology (C.W.), National Clinical Research Center for Geriatric Disorders (Z.C., L.S., B.T., H.J.), Xiangya Hospital, Central South University; Department of Neurology (Z.L.), The Second Xiangya Hospital, Central South University; Key Laboratory of Hunan Province in Neurodegenerative Disorders (Z.C., L.S., J.L., B.T., H.J.), Center for Medical Genetics School of Life Sciences (K.X., J.L., C.C.), Hunan Key Laboratory of Medical Genetics (K.X., J.L., C.C.), School of Computer Science and Engineering (R.Q.), and School of Basic Medical Science (H.J.), Central South University, Changsha, Hunan, China; Department of Neurology (T.K.), University of Bonn; and German Center for Neurodegenerative Diseases (DZNE) (T.K.), Bonn, Germany
| | - Jinchen Li
- From the Department of Neurology (L.P., Z.C., M.L., L.L., H.P., Y.S., Y.P., Q.D., S.W., G.Z., L.W., H.Y., L.H., Y.X., Z.T., N.W., Y.G., X.H., L.S., J.L., B.T., H.J.), Department of Pathology (C.W.), National Clinical Research Center for Geriatric Disorders (Z.C., L.S., B.T., H.J.), Xiangya Hospital, Central South University; Department of Neurology (Z.L.), The Second Xiangya Hospital, Central South University; Key Laboratory of Hunan Province in Neurodegenerative Disorders (Z.C., L.S., J.L., B.T., H.J.), Center for Medical Genetics School of Life Sciences (K.X., J.L., C.C.), Hunan Key Laboratory of Medical Genetics (K.X., J.L., C.C.), School of Computer Science and Engineering (R.Q.), and School of Basic Medical Science (H.J.), Central South University, Changsha, Hunan, China; Department of Neurology (T.K.), University of Bonn; and German Center for Neurodegenerative Diseases (DZNE) (T.K.), Bonn, Germany
| | - Chao Chen
- From the Department of Neurology (L.P., Z.C., M.L., L.L., H.P., Y.S., Y.P., Q.D., S.W., G.Z., L.W., H.Y., L.H., Y.X., Z.T., N.W., Y.G., X.H., L.S., J.L., B.T., H.J.), Department of Pathology (C.W.), National Clinical Research Center for Geriatric Disorders (Z.C., L.S., B.T., H.J.), Xiangya Hospital, Central South University; Department of Neurology (Z.L.), The Second Xiangya Hospital, Central South University; Key Laboratory of Hunan Province in Neurodegenerative Disorders (Z.C., L.S., J.L., B.T., H.J.), Center for Medical Genetics School of Life Sciences (K.X., J.L., C.C.), Hunan Key Laboratory of Medical Genetics (K.X., J.L., C.C.), School of Computer Science and Engineering (R.Q.), and School of Basic Medical Science (H.J.), Central South University, Changsha, Hunan, China; Department of Neurology (T.K.), University of Bonn; and German Center for Neurodegenerative Diseases (DZNE) (T.K.), Bonn, Germany
| | - Rong Qiu
- From the Department of Neurology (L.P., Z.C., M.L., L.L., H.P., Y.S., Y.P., Q.D., S.W., G.Z., L.W., H.Y., L.H., Y.X., Z.T., N.W., Y.G., X.H., L.S., J.L., B.T., H.J.), Department of Pathology (C.W.), National Clinical Research Center for Geriatric Disorders (Z.C., L.S., B.T., H.J.), Xiangya Hospital, Central South University; Department of Neurology (Z.L.), The Second Xiangya Hospital, Central South University; Key Laboratory of Hunan Province in Neurodegenerative Disorders (Z.C., L.S., J.L., B.T., H.J.), Center for Medical Genetics School of Life Sciences (K.X., J.L., C.C.), Hunan Key Laboratory of Medical Genetics (K.X., J.L., C.C.), School of Computer Science and Engineering (R.Q.), and School of Basic Medical Science (H.J.), Central South University, Changsha, Hunan, China; Department of Neurology (T.K.), University of Bonn; and German Center for Neurodegenerative Diseases (DZNE) (T.K.), Bonn, Germany
| | - Thomas Klockgether
- From the Department of Neurology (L.P., Z.C., M.L., L.L., H.P., Y.S., Y.P., Q.D., S.W., G.Z., L.W., H.Y., L.H., Y.X., Z.T., N.W., Y.G., X.H., L.S., J.L., B.T., H.J.), Department of Pathology (C.W.), National Clinical Research Center for Geriatric Disorders (Z.C., L.S., B.T., H.J.), Xiangya Hospital, Central South University; Department of Neurology (Z.L.), The Second Xiangya Hospital, Central South University; Key Laboratory of Hunan Province in Neurodegenerative Disorders (Z.C., L.S., J.L., B.T., H.J.), Center for Medical Genetics School of Life Sciences (K.X., J.L., C.C.), Hunan Key Laboratory of Medical Genetics (K.X., J.L., C.C.), School of Computer Science and Engineering (R.Q.), and School of Basic Medical Science (H.J.), Central South University, Changsha, Hunan, China; Department of Neurology (T.K.), University of Bonn; and German Center for Neurodegenerative Diseases (DZNE) (T.K.), Bonn, Germany
| | - Beisha Tang
- From the Department of Neurology (L.P., Z.C., M.L., L.L., H.P., Y.S., Y.P., Q.D., S.W., G.Z., L.W., H.Y., L.H., Y.X., Z.T., N.W., Y.G., X.H., L.S., J.L., B.T., H.J.), Department of Pathology (C.W.), National Clinical Research Center for Geriatric Disorders (Z.C., L.S., B.T., H.J.), Xiangya Hospital, Central South University; Department of Neurology (Z.L.), The Second Xiangya Hospital, Central South University; Key Laboratory of Hunan Province in Neurodegenerative Disorders (Z.C., L.S., J.L., B.T., H.J.), Center for Medical Genetics School of Life Sciences (K.X., J.L., C.C.), Hunan Key Laboratory of Medical Genetics (K.X., J.L., C.C.), School of Computer Science and Engineering (R.Q.), and School of Basic Medical Science (H.J.), Central South University, Changsha, Hunan, China; Department of Neurology (T.K.), University of Bonn; and German Center for Neurodegenerative Diseases (DZNE) (T.K.), Bonn, Germany
| | - Hong Jiang
- From the Department of Neurology (L.P., Z.C., M.L., L.L., H.P., Y.S., Y.P., Q.D., S.W., G.Z., L.W., H.Y., L.H., Y.X., Z.T., N.W., Y.G., X.H., L.S., J.L., B.T., H.J.), Department of Pathology (C.W.), National Clinical Research Center for Geriatric Disorders (Z.C., L.S., B.T., H.J.), Xiangya Hospital, Central South University; Department of Neurology (Z.L.), The Second Xiangya Hospital, Central South University; Key Laboratory of Hunan Province in Neurodegenerative Disorders (Z.C., L.S., J.L., B.T., H.J.), Center for Medical Genetics School of Life Sciences (K.X., J.L., C.C.), Hunan Key Laboratory of Medical Genetics (K.X., J.L., C.C.), School of Computer Science and Engineering (R.Q.), and School of Basic Medical Science (H.J.), Central South University, Changsha, Hunan, China; Department of Neurology (T.K.), University of Bonn; and German Center for Neurodegenerative Diseases (DZNE) (T.K.), Bonn, Germany.
| |
Collapse
|
6
|
Ding D, Wang C, Chen Z, Xia K, Tang B, Qiu R, Jiang H. Polyglutamine-expanded ataxin3 alter specific gene expressions through changing DNA methylation status in SCA3/MJD. Aging (Albany NY) 2020; 13:3680-3698. [PMID: 33411688 PMCID: PMC7906150 DOI: 10.18632/aging.202331] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2020] [Accepted: 10/27/2020] [Indexed: 11/25/2022]
Abstract
DNA methylation has recently been linked to transcriptional dysregulation and neuronal dysfunction in polyglutamine (polyQ) disease. This study aims to determine whether (CAG)n expansion in ATXN3 perturbs DNA methylation status and affects gene expression. We analyzed DNA methylation throughout the genome using reduced representation bisulfite sequencing (RRBS) and confirmed the results using MethylTarget sequencing. Dynamic changes in DNA methylation, transcriptional and translational levels of specific genes were detected using BSP, qRT-PCR and western blot. In total, 135 differentially methylated regions (DMRs) were identified between SCA3/MJD and WT mouse cerebellum. KEGG analysis revealed differentially methylated genes involved in amino acid metabolism, Hedgehog signaling pathway, thyroid cancer, tumorigenesis and other pathways. We focused on DMRs that were directly associated with gene expression. On this basis, we further assessed 7 genes, including 13 DMRs, for DNA methylation validation and gene expression. We found that the methylation status of the DMRs of En1 and Nkx2-1 was negatively associated with their transcriptional and translational levels and that alteration of the DNA methylation status of DMRs and the corresponding transcription occurred before dyskinesia in SCA3/MJD mice. These results revealed novel DNA methylation-regulated genes, En1 and Nkx2-1, which may be useful for understanding the pathogenesis of SCA3/MJD.
Collapse
Affiliation(s)
- Dongxue Ding
- Department of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan, P.R. China
| | - Chunrong Wang
- Department of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan, P.R. China
| | - Zhao Chen
- Department of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan, P.R. China
| | - Kun Xia
- State Key Laboratory of Medical Genetics, Central South University, Changsha, Hunan, P.R. China
| | - Beisha Tang
- Department of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan, P.R. China.,State Key Laboratory of Medical Genetics, Central South University, Changsha, Hunan, P.R. China.,Key Laboratory of Hunan Province in Neurodegenerative Disorders, Central South University, Changsha, Hunan, P.R. China.,National Clinical Research Center for Geriatric Diseases, Changsha, Hunan, P. R. China
| | - Rong Qiu
- School of Information Science and Engineering, Central South University, Changsha, China
| | - Hong Jiang
- Department of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan, P.R. China.,State Key Laboratory of Medical Genetics, Central South University, Changsha, Hunan, P.R. China.,Key Laboratory of Hunan Province in Neurodegenerative Disorders, Central South University, Changsha, Hunan, P.R. China.,National Clinical Research Center for Geriatric Diseases, Changsha, Hunan, P. R. China
| |
Collapse
|
7
|
Peng L, Chen Z, Chen T, Lei L, Long Z, Liu M, Deng Q, Yuan H, Zou G, Wan L, Wang C, Peng H, Shi Y, Wang P, Peng Y, Wang S, He L, Xie Y, Tang Z, Wan N, Gong Y, Hou X, Shen L, Xia K, Li J, Chen C, Zhang Z, Qiu R, Tang B, Jiang H. Prediction of the Age at Onset of Spinocerebellar Ataxia Type 3 with Machine Learning. Mov Disord 2020; 36:216-224. [PMID: 32991004 DOI: 10.1002/mds.28311] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2020] [Revised: 08/31/2020] [Accepted: 09/03/2020] [Indexed: 12/13/2022] Open
Abstract
BACKGROUND In polyglutamine (polyQ) disease, the investigation of the prediction of a patient's age at onset (AAO) facilitates the development of disease-modifying intervention and underpins the delay of disease onset and progression. Few polyQ disease studies have evaluated AAO predicted by machine-learning algorithms and linear regression methods. OBJECTIVE The objective of this study was to develop a machine-learning model for AAO prediction in the largest spinocerebellar ataxia type 3/Machado-Joseph disease (SCA3/MJD) population from mainland China. METHODS In this observational study, we introduced an innovative approach by systematically comparing the performance of 7 machine-learning algorithms with linear regression to explore AAO prediction in SCA3/MJD using CAG expansions of 10 polyQ-related genes, sex, and parental origin. RESULTS Similar prediction performance of testing set and training set in each models were identified and few overfitting of training data was observed. Overall, the machine-learning-based XGBoost model exhibited the most favorable performance in AAO prediction over the traditional linear regression method and other 6 machine-learning algorithms for the training set and testing set. The optimal XGBoost model achieved mean absolute error, root mean square error, and median absolute error of 5.56, 7.13, 4.15 years, respectively, in testing set 1, with mean absolute error (4.78 years), root mean square error (6.31 years), and median absolute error (3.59 years) in testing set 2. CONCLUSION Machine-learning algorithms can be used to predict AAO in patients with SCA3/MJD. The optimal XGBoost algorithm can provide a good reference for the establishment and optimization of prediction models for SCA3/MJD or other polyQ diseases. © 2020 International Parkinson and Movement Disorder Society.
Collapse
Affiliation(s)
- Linliu Peng
- Department of Neurology, Xiangya Hospital, Central South University, Changsha, China
| | - Zhao Chen
- Department of Neurology, Xiangya Hospital, Central South University, Changsha, China.,National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China.,Key Laboratory of Hunan Province in Neurodegenerative Disorders, Central South University, Changsha, China
| | - Tiankai Chen
- School of Computer Science and Engineering, Central South University, Changsha, China
| | - Lijing Lei
- Department of Neurology, Xiangya Hospital, Central South University, Changsha, China
| | - Zhe Long
- Department of Neurology, The Second Xiangya Hospital, Central South University, Changsha, China
| | - Mingjie Liu
- Department of Neurology, Xiangya Hospital, Central South University, Changsha, China
| | - Qi Deng
- Department of Neurology, Xiangya Hospital, Central South University, Changsha, China
| | - Hongyu Yuan
- Department of Neurology, Xiangya Hospital, Central South University, Changsha, China
| | - Guangdong Zou
- Department of Neurology, Xiangya Hospital, Central South University, Changsha, China
| | - Linlin Wan
- Department of Neurology, Xiangya Hospital, Central South University, Changsha, China
| | - Chunrong Wang
- Department of Pathology, Xiangya Hospital, Central South University, Changsha, China
| | - Huirong Peng
- Department of Neurology, Xiangya Hospital, Central South University, Changsha, China
| | - Yuting Shi
- Department of Neurology, Xiangya Hospital, Central South University, Changsha, China
| | - Puzhi Wang
- Department of Neurology, Xiangya Hospital, Central South University, Changsha, China
| | - Yun Peng
- Department of Neurology, Xiangya Hospital, Central South University, Changsha, China
| | - Shang Wang
- Department of Neurology, Xiangya Hospital, Central South University, Changsha, China
| | - Lang He
- Department of Neurology, Xiangya Hospital, Central South University, Changsha, China
| | - Yue Xie
- Department of Neurology, Xiangya Hospital, Central South University, Changsha, China
| | - Zhichao Tang
- Department of Neurology, Xiangya Hospital, Central South University, Changsha, China
| | - Na Wan
- Department of Neurology, Xiangya Hospital, Central South University, Changsha, China
| | - Yiqing Gong
- Department of Neurology, Xiangya Hospital, Central South University, Changsha, China
| | - Xuan Hou
- Department of Neurology, Xiangya Hospital, Central South University, Changsha, China
| | - Lu Shen
- Department of Neurology, Xiangya Hospital, Central South University, Changsha, China.,National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China.,Key Laboratory of Hunan Province in Neurodegenerative Disorders, Central South University, Changsha, China
| | - Kun Xia
- Center for Medical Genetics, School of Life Sciences, Central South University, Changsha, China.,Hunan Key Laboratory of Medical Genetics, Central South University, Changsha, China
| | - Jinchen Li
- Department of Neurology, Xiangya Hospital, Central South University, Changsha, China.,National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China.,Center for Medical Genetics, School of Life Sciences, Central South University, Changsha, China.,Hunan Key Laboratory of Medical Genetics, Central South University, Changsha, China
| | - Chao Chen
- Center for Medical Genetics, School of Life Sciences, Central South University, Changsha, China.,Hunan Key Laboratory of Medical Genetics, Central South University, Changsha, China
| | - Zuping Zhang
- School of Computer Science and Engineering, Central South University, Changsha, China
| | - Rong Qiu
- School of Computer Science and Engineering, Central South University, Changsha, China
| | - Beisha Tang
- Department of Neurology, Xiangya Hospital, Central South University, Changsha, China.,National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China.,Key Laboratory of Hunan Province in Neurodegenerative Disorders, Central South University, Changsha, China
| | - Hong Jiang
- Department of Neurology, Xiangya Hospital, Central South University, Changsha, China.,National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China.,Key Laboratory of Hunan Province in Neurodegenerative Disorders, Central South University, Changsha, China
| |
Collapse
|
8
|
Peng Y, Zhang Y, Chen Z, Peng H, Wan N, Zhang J, Tang J, Wang P, Xie Y, Cai Q, Liu S, Zhang X, Wang C, Yuan H, Li T, Wan L, Shi Y, Qiu R, Klockgether T, Tang B, Liao W, Jiang H. Association of serum neurofilament light and disease severity in patients with spinocerebellar ataxia type 3. Neurology 2020; 95:e2977-e2987. [PMID: 32817181 DOI: 10.1212/wnl.0000000000010671] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2019] [Accepted: 06/03/2020] [Indexed: 12/11/2022] Open
Abstract
OBJECTIVE To investigate serum neurofilament light protein (sNfL) levels in patients with spinocerebellar ataxia type 3 (SCA3) and to determine whether they are associated with disease severity. METHODS This cross-sectional study enrolled 185 healthy controls and 235 ATXN3 mutation carriers (17 asymptomatic stage, 20 preclinical stage, and 198 ataxic stage). We measured sNfL levels with the single molecule array (Simoa) platform. Clinical disease severity was assessed using the Scale of Assessment and Rating of Ataxia (SARA) and the Inventory of Nonataxia Signs (INAS). In a subgroup of 50 ataxic stage patients, we further evaluated the gray matter volume and the integrity of white matter fibers by MRI. RESULTS sNfL concentrations were elevated in asymptomatic, preclinical, and ataxic ATXN3 mutation carriers compared to controls (12.18 [10.20-13.92], 21.84 [18.37-23.45], 36.06 [30.04-45.90], and 8.24 [5.92-10.84] pg/mL, median [interquartile range], respectively, p < 0.001). sNfL correlated with SARA (r = 0.406, 95% confidence interval [CI] 0.284-0.515, p < 0.0001) and INAS (r = 0.375, 95% CI 0.250-0.487, p < 0.0001), and remained significant after adjustment for age and CAG repeats. In addition, we observed negative correlations of the sNfL with gray matter volume in the left precentral gyrus and the left paracentral lobule as well as with the mean diffusivity in widespread white matter tracts. CONCLUSION Our results demonstrate that sNfL levels are increased in SCA3 and are associated with clinical disease severity, which supports sNfL as a biomarker for disease severity in SCA3. CLASSIFICATION OF EVIDENCE This study provides Class II evidence that in patients with SCA3, sNfL elevations are associated with clinical disease severity.
Collapse
Affiliation(s)
- Yun Peng
- From the Departments of Neurology (Y.P., Z.C., H.P., N.W., P.W., Y.X., H.Y., T.L., L.W., Y.S., B.T., H.J.), Radiology (Y.Z., J.T., W.L.), and Pathology (C.W.), Health Management Center (S.L., X.Z.), and National Clinical Research Center for Geriatric Diseases (B.T., W.L., H.J.), Xiangya Hospital, and School of Computer Science and Engineering (R.Q.), Laboratory of Medical Genetics (B.T., H.J.), and Key Laboratory of Hunan Province in Neurodegenerative Disorders (B.T., H.J.), Central South University, Changsha, Hunan, China; Department of Human Genetics (J.Z.), Emory University School of Medicine, Atlanta, GA; Institute of Chemical Biology and Nanomedicine (ICBN) (Q.C.), Hunan University, Changsha, Hunan, China; Department of Neurology (T.K.), University of Bonn; and German Center for Neurodegenerative Diseases (DZNE) (T.K.), Bonn, Germany
| | - Youming Zhang
- From the Departments of Neurology (Y.P., Z.C., H.P., N.W., P.W., Y.X., H.Y., T.L., L.W., Y.S., B.T., H.J.), Radiology (Y.Z., J.T., W.L.), and Pathology (C.W.), Health Management Center (S.L., X.Z.), and National Clinical Research Center for Geriatric Diseases (B.T., W.L., H.J.), Xiangya Hospital, and School of Computer Science and Engineering (R.Q.), Laboratory of Medical Genetics (B.T., H.J.), and Key Laboratory of Hunan Province in Neurodegenerative Disorders (B.T., H.J.), Central South University, Changsha, Hunan, China; Department of Human Genetics (J.Z.), Emory University School of Medicine, Atlanta, GA; Institute of Chemical Biology and Nanomedicine (ICBN) (Q.C.), Hunan University, Changsha, Hunan, China; Department of Neurology (T.K.), University of Bonn; and German Center for Neurodegenerative Diseases (DZNE) (T.K.), Bonn, Germany
| | - Zhao Chen
- From the Departments of Neurology (Y.P., Z.C., H.P., N.W., P.W., Y.X., H.Y., T.L., L.W., Y.S., B.T., H.J.), Radiology (Y.Z., J.T., W.L.), and Pathology (C.W.), Health Management Center (S.L., X.Z.), and National Clinical Research Center for Geriatric Diseases (B.T., W.L., H.J.), Xiangya Hospital, and School of Computer Science and Engineering (R.Q.), Laboratory of Medical Genetics (B.T., H.J.), and Key Laboratory of Hunan Province in Neurodegenerative Disorders (B.T., H.J.), Central South University, Changsha, Hunan, China; Department of Human Genetics (J.Z.), Emory University School of Medicine, Atlanta, GA; Institute of Chemical Biology and Nanomedicine (ICBN) (Q.C.), Hunan University, Changsha, Hunan, China; Department of Neurology (T.K.), University of Bonn; and German Center for Neurodegenerative Diseases (DZNE) (T.K.), Bonn, Germany
| | - Huirong Peng
- From the Departments of Neurology (Y.P., Z.C., H.P., N.W., P.W., Y.X., H.Y., T.L., L.W., Y.S., B.T., H.J.), Radiology (Y.Z., J.T., W.L.), and Pathology (C.W.), Health Management Center (S.L., X.Z.), and National Clinical Research Center for Geriatric Diseases (B.T., W.L., H.J.), Xiangya Hospital, and School of Computer Science and Engineering (R.Q.), Laboratory of Medical Genetics (B.T., H.J.), and Key Laboratory of Hunan Province in Neurodegenerative Disorders (B.T., H.J.), Central South University, Changsha, Hunan, China; Department of Human Genetics (J.Z.), Emory University School of Medicine, Atlanta, GA; Institute of Chemical Biology and Nanomedicine (ICBN) (Q.C.), Hunan University, Changsha, Hunan, China; Department of Neurology (T.K.), University of Bonn; and German Center for Neurodegenerative Diseases (DZNE) (T.K.), Bonn, Germany
| | - Na Wan
- From the Departments of Neurology (Y.P., Z.C., H.P., N.W., P.W., Y.X., H.Y., T.L., L.W., Y.S., B.T., H.J.), Radiology (Y.Z., J.T., W.L.), and Pathology (C.W.), Health Management Center (S.L., X.Z.), and National Clinical Research Center for Geriatric Diseases (B.T., W.L., H.J.), Xiangya Hospital, and School of Computer Science and Engineering (R.Q.), Laboratory of Medical Genetics (B.T., H.J.), and Key Laboratory of Hunan Province in Neurodegenerative Disorders (B.T., H.J.), Central South University, Changsha, Hunan, China; Department of Human Genetics (J.Z.), Emory University School of Medicine, Atlanta, GA; Institute of Chemical Biology and Nanomedicine (ICBN) (Q.C.), Hunan University, Changsha, Hunan, China; Department of Neurology (T.K.), University of Bonn; and German Center for Neurodegenerative Diseases (DZNE) (T.K.), Bonn, Germany
| | - Jennifer Zhang
- From the Departments of Neurology (Y.P., Z.C., H.P., N.W., P.W., Y.X., H.Y., T.L., L.W., Y.S., B.T., H.J.), Radiology (Y.Z., J.T., W.L.), and Pathology (C.W.), Health Management Center (S.L., X.Z.), and National Clinical Research Center for Geriatric Diseases (B.T., W.L., H.J.), Xiangya Hospital, and School of Computer Science and Engineering (R.Q.), Laboratory of Medical Genetics (B.T., H.J.), and Key Laboratory of Hunan Province in Neurodegenerative Disorders (B.T., H.J.), Central South University, Changsha, Hunan, China; Department of Human Genetics (J.Z.), Emory University School of Medicine, Atlanta, GA; Institute of Chemical Biology and Nanomedicine (ICBN) (Q.C.), Hunan University, Changsha, Hunan, China; Department of Neurology (T.K.), University of Bonn; and German Center for Neurodegenerative Diseases (DZNE) (T.K.), Bonn, Germany
| | - Jingyi Tang
- From the Departments of Neurology (Y.P., Z.C., H.P., N.W., P.W., Y.X., H.Y., T.L., L.W., Y.S., B.T., H.J.), Radiology (Y.Z., J.T., W.L.), and Pathology (C.W.), Health Management Center (S.L., X.Z.), and National Clinical Research Center for Geriatric Diseases (B.T., W.L., H.J.), Xiangya Hospital, and School of Computer Science and Engineering (R.Q.), Laboratory of Medical Genetics (B.T., H.J.), and Key Laboratory of Hunan Province in Neurodegenerative Disorders (B.T., H.J.), Central South University, Changsha, Hunan, China; Department of Human Genetics (J.Z.), Emory University School of Medicine, Atlanta, GA; Institute of Chemical Biology and Nanomedicine (ICBN) (Q.C.), Hunan University, Changsha, Hunan, China; Department of Neurology (T.K.), University of Bonn; and German Center for Neurodegenerative Diseases (DZNE) (T.K.), Bonn, Germany
| | - Puzhi Wang
- From the Departments of Neurology (Y.P., Z.C., H.P., N.W., P.W., Y.X., H.Y., T.L., L.W., Y.S., B.T., H.J.), Radiology (Y.Z., J.T., W.L.), and Pathology (C.W.), Health Management Center (S.L., X.Z.), and National Clinical Research Center for Geriatric Diseases (B.T., W.L., H.J.), Xiangya Hospital, and School of Computer Science and Engineering (R.Q.), Laboratory of Medical Genetics (B.T., H.J.), and Key Laboratory of Hunan Province in Neurodegenerative Disorders (B.T., H.J.), Central South University, Changsha, Hunan, China; Department of Human Genetics (J.Z.), Emory University School of Medicine, Atlanta, GA; Institute of Chemical Biology and Nanomedicine (ICBN) (Q.C.), Hunan University, Changsha, Hunan, China; Department of Neurology (T.K.), University of Bonn; and German Center for Neurodegenerative Diseases (DZNE) (T.K.), Bonn, Germany
| | - Yue Xie
- From the Departments of Neurology (Y.P., Z.C., H.P., N.W., P.W., Y.X., H.Y., T.L., L.W., Y.S., B.T., H.J.), Radiology (Y.Z., J.T., W.L.), and Pathology (C.W.), Health Management Center (S.L., X.Z.), and National Clinical Research Center for Geriatric Diseases (B.T., W.L., H.J.), Xiangya Hospital, and School of Computer Science and Engineering (R.Q.), Laboratory of Medical Genetics (B.T., H.J.), and Key Laboratory of Hunan Province in Neurodegenerative Disorders (B.T., H.J.), Central South University, Changsha, Hunan, China; Department of Human Genetics (J.Z.), Emory University School of Medicine, Atlanta, GA; Institute of Chemical Biology and Nanomedicine (ICBN) (Q.C.), Hunan University, Changsha, Hunan, China; Department of Neurology (T.K.), University of Bonn; and German Center for Neurodegenerative Diseases (DZNE) (T.K.), Bonn, Germany
| | - Qiyong Cai
- From the Departments of Neurology (Y.P., Z.C., H.P., N.W., P.W., Y.X., H.Y., T.L., L.W., Y.S., B.T., H.J.), Radiology (Y.Z., J.T., W.L.), and Pathology (C.W.), Health Management Center (S.L., X.Z.), and National Clinical Research Center for Geriatric Diseases (B.T., W.L., H.J.), Xiangya Hospital, and School of Computer Science and Engineering (R.Q.), Laboratory of Medical Genetics (B.T., H.J.), and Key Laboratory of Hunan Province in Neurodegenerative Disorders (B.T., H.J.), Central South University, Changsha, Hunan, China; Department of Human Genetics (J.Z.), Emory University School of Medicine, Atlanta, GA; Institute of Chemical Biology and Nanomedicine (ICBN) (Q.C.), Hunan University, Changsha, Hunan, China; Department of Neurology (T.K.), University of Bonn; and German Center for Neurodegenerative Diseases (DZNE) (T.K.), Bonn, Germany
| | - Shaohui Liu
- From the Departments of Neurology (Y.P., Z.C., H.P., N.W., P.W., Y.X., H.Y., T.L., L.W., Y.S., B.T., H.J.), Radiology (Y.Z., J.T., W.L.), and Pathology (C.W.), Health Management Center (S.L., X.Z.), and National Clinical Research Center for Geriatric Diseases (B.T., W.L., H.J.), Xiangya Hospital, and School of Computer Science and Engineering (R.Q.), Laboratory of Medical Genetics (B.T., H.J.), and Key Laboratory of Hunan Province in Neurodegenerative Disorders (B.T., H.J.), Central South University, Changsha, Hunan, China; Department of Human Genetics (J.Z.), Emory University School of Medicine, Atlanta, GA; Institute of Chemical Biology and Nanomedicine (ICBN) (Q.C.), Hunan University, Changsha, Hunan, China; Department of Neurology (T.K.), University of Bonn; and German Center for Neurodegenerative Diseases (DZNE) (T.K.), Bonn, Germany
| | - Xuewei Zhang
- From the Departments of Neurology (Y.P., Z.C., H.P., N.W., P.W., Y.X., H.Y., T.L., L.W., Y.S., B.T., H.J.), Radiology (Y.Z., J.T., W.L.), and Pathology (C.W.), Health Management Center (S.L., X.Z.), and National Clinical Research Center for Geriatric Diseases (B.T., W.L., H.J.), Xiangya Hospital, and School of Computer Science and Engineering (R.Q.), Laboratory of Medical Genetics (B.T., H.J.), and Key Laboratory of Hunan Province in Neurodegenerative Disorders (B.T., H.J.), Central South University, Changsha, Hunan, China; Department of Human Genetics (J.Z.), Emory University School of Medicine, Atlanta, GA; Institute of Chemical Biology and Nanomedicine (ICBN) (Q.C.), Hunan University, Changsha, Hunan, China; Department of Neurology (T.K.), University of Bonn; and German Center for Neurodegenerative Diseases (DZNE) (T.K.), Bonn, Germany
| | - Chunrong Wang
- From the Departments of Neurology (Y.P., Z.C., H.P., N.W., P.W., Y.X., H.Y., T.L., L.W., Y.S., B.T., H.J.), Radiology (Y.Z., J.T., W.L.), and Pathology (C.W.), Health Management Center (S.L., X.Z.), and National Clinical Research Center for Geriatric Diseases (B.T., W.L., H.J.), Xiangya Hospital, and School of Computer Science and Engineering (R.Q.), Laboratory of Medical Genetics (B.T., H.J.), and Key Laboratory of Hunan Province in Neurodegenerative Disorders (B.T., H.J.), Central South University, Changsha, Hunan, China; Department of Human Genetics (J.Z.), Emory University School of Medicine, Atlanta, GA; Institute of Chemical Biology and Nanomedicine (ICBN) (Q.C.), Hunan University, Changsha, Hunan, China; Department of Neurology (T.K.), University of Bonn; and German Center for Neurodegenerative Diseases (DZNE) (T.K.), Bonn, Germany
| | - Hongyu Yuan
- From the Departments of Neurology (Y.P., Z.C., H.P., N.W., P.W., Y.X., H.Y., T.L., L.W., Y.S., B.T., H.J.), Radiology (Y.Z., J.T., W.L.), and Pathology (C.W.), Health Management Center (S.L., X.Z.), and National Clinical Research Center for Geriatric Diseases (B.T., W.L., H.J.), Xiangya Hospital, and School of Computer Science and Engineering (R.Q.), Laboratory of Medical Genetics (B.T., H.J.), and Key Laboratory of Hunan Province in Neurodegenerative Disorders (B.T., H.J.), Central South University, Changsha, Hunan, China; Department of Human Genetics (J.Z.), Emory University School of Medicine, Atlanta, GA; Institute of Chemical Biology and Nanomedicine (ICBN) (Q.C.), Hunan University, Changsha, Hunan, China; Department of Neurology (T.K.), University of Bonn; and German Center for Neurodegenerative Diseases (DZNE) (T.K.), Bonn, Germany
| | - Tianjiao Li
- From the Departments of Neurology (Y.P., Z.C., H.P., N.W., P.W., Y.X., H.Y., T.L., L.W., Y.S., B.T., H.J.), Radiology (Y.Z., J.T., W.L.), and Pathology (C.W.), Health Management Center (S.L., X.Z.), and National Clinical Research Center for Geriatric Diseases (B.T., W.L., H.J.), Xiangya Hospital, and School of Computer Science and Engineering (R.Q.), Laboratory of Medical Genetics (B.T., H.J.), and Key Laboratory of Hunan Province in Neurodegenerative Disorders (B.T., H.J.), Central South University, Changsha, Hunan, China; Department of Human Genetics (J.Z.), Emory University School of Medicine, Atlanta, GA; Institute of Chemical Biology and Nanomedicine (ICBN) (Q.C.), Hunan University, Changsha, Hunan, China; Department of Neurology (T.K.), University of Bonn; and German Center for Neurodegenerative Diseases (DZNE) (T.K.), Bonn, Germany.
| | - Linlin Wan
- From the Departments of Neurology (Y.P., Z.C., H.P., N.W., P.W., Y.X., H.Y., T.L., L.W., Y.S., B.T., H.J.), Radiology (Y.Z., J.T., W.L.), and Pathology (C.W.), Health Management Center (S.L., X.Z.), and National Clinical Research Center for Geriatric Diseases (B.T., W.L., H.J.), Xiangya Hospital, and School of Computer Science and Engineering (R.Q.), Laboratory of Medical Genetics (B.T., H.J.), and Key Laboratory of Hunan Province in Neurodegenerative Disorders (B.T., H.J.), Central South University, Changsha, Hunan, China; Department of Human Genetics (J.Z.), Emory University School of Medicine, Atlanta, GA; Institute of Chemical Biology and Nanomedicine (ICBN) (Q.C.), Hunan University, Changsha, Hunan, China; Department of Neurology (T.K.), University of Bonn; and German Center for Neurodegenerative Diseases (DZNE) (T.K.), Bonn, Germany
| | - Yuting Shi
- From the Departments of Neurology (Y.P., Z.C., H.P., N.W., P.W., Y.X., H.Y., T.L., L.W., Y.S., B.T., H.J.), Radiology (Y.Z., J.T., W.L.), and Pathology (C.W.), Health Management Center (S.L., X.Z.), and National Clinical Research Center for Geriatric Diseases (B.T., W.L., H.J.), Xiangya Hospital, and School of Computer Science and Engineering (R.Q.), Laboratory of Medical Genetics (B.T., H.J.), and Key Laboratory of Hunan Province in Neurodegenerative Disorders (B.T., H.J.), Central South University, Changsha, Hunan, China; Department of Human Genetics (J.Z.), Emory University School of Medicine, Atlanta, GA; Institute of Chemical Biology and Nanomedicine (ICBN) (Q.C.), Hunan University, Changsha, Hunan, China; Department of Neurology (T.K.), University of Bonn; and German Center for Neurodegenerative Diseases (DZNE) (T.K.), Bonn, Germany
| | - Rong Qiu
- From the Departments of Neurology (Y.P., Z.C., H.P., N.W., P.W., Y.X., H.Y., T.L., L.W., Y.S., B.T., H.J.), Radiology (Y.Z., J.T., W.L.), and Pathology (C.W.), Health Management Center (S.L., X.Z.), and National Clinical Research Center for Geriatric Diseases (B.T., W.L., H.J.), Xiangya Hospital, and School of Computer Science and Engineering (R.Q.), Laboratory of Medical Genetics (B.T., H.J.), and Key Laboratory of Hunan Province in Neurodegenerative Disorders (B.T., H.J.), Central South University, Changsha, Hunan, China; Department of Human Genetics (J.Z.), Emory University School of Medicine, Atlanta, GA; Institute of Chemical Biology and Nanomedicine (ICBN) (Q.C.), Hunan University, Changsha, Hunan, China; Department of Neurology (T.K.), University of Bonn; and German Center for Neurodegenerative Diseases (DZNE) (T.K.), Bonn, Germany
| | - Thomas Klockgether
- From the Departments of Neurology (Y.P., Z.C., H.P., N.W., P.W., Y.X., H.Y., T.L., L.W., Y.S., B.T., H.J.), Radiology (Y.Z., J.T., W.L.), and Pathology (C.W.), Health Management Center (S.L., X.Z.), and National Clinical Research Center for Geriatric Diseases (B.T., W.L., H.J.), Xiangya Hospital, and School of Computer Science and Engineering (R.Q.), Laboratory of Medical Genetics (B.T., H.J.), and Key Laboratory of Hunan Province in Neurodegenerative Disorders (B.T., H.J.), Central South University, Changsha, Hunan, China; Department of Human Genetics (J.Z.), Emory University School of Medicine, Atlanta, GA; Institute of Chemical Biology and Nanomedicine (ICBN) (Q.C.), Hunan University, Changsha, Hunan, China; Department of Neurology (T.K.), University of Bonn; and German Center for Neurodegenerative Diseases (DZNE) (T.K.), Bonn, Germany
| | - Beisha Tang
- From the Departments of Neurology (Y.P., Z.C., H.P., N.W., P.W., Y.X., H.Y., T.L., L.W., Y.S., B.T., H.J.), Radiology (Y.Z., J.T., W.L.), and Pathology (C.W.), Health Management Center (S.L., X.Z.), and National Clinical Research Center for Geriatric Diseases (B.T., W.L., H.J.), Xiangya Hospital, and School of Computer Science and Engineering (R.Q.), Laboratory of Medical Genetics (B.T., H.J.), and Key Laboratory of Hunan Province in Neurodegenerative Disorders (B.T., H.J.), Central South University, Changsha, Hunan, China; Department of Human Genetics (J.Z.), Emory University School of Medicine, Atlanta, GA; Institute of Chemical Biology and Nanomedicine (ICBN) (Q.C.), Hunan University, Changsha, Hunan, China; Department of Neurology (T.K.), University of Bonn; and German Center for Neurodegenerative Diseases (DZNE) (T.K.), Bonn, Germany
| | - Weihua Liao
- From the Departments of Neurology (Y.P., Z.C., H.P., N.W., P.W., Y.X., H.Y., T.L., L.W., Y.S., B.T., H.J.), Radiology (Y.Z., J.T., W.L.), and Pathology (C.W.), Health Management Center (S.L., X.Z.), and National Clinical Research Center for Geriatric Diseases (B.T., W.L., H.J.), Xiangya Hospital, and School of Computer Science and Engineering (R.Q.), Laboratory of Medical Genetics (B.T., H.J.), and Key Laboratory of Hunan Province in Neurodegenerative Disorders (B.T., H.J.), Central South University, Changsha, Hunan, China; Department of Human Genetics (J.Z.), Emory University School of Medicine, Atlanta, GA; Institute of Chemical Biology and Nanomedicine (ICBN) (Q.C.), Hunan University, Changsha, Hunan, China; Department of Neurology (T.K.), University of Bonn; and German Center for Neurodegenerative Diseases (DZNE) (T.K.), Bonn, Germany.
| | - Hong Jiang
- From the Departments of Neurology (Y.P., Z.C., H.P., N.W., P.W., Y.X., H.Y., T.L., L.W., Y.S., B.T., H.J.), Radiology (Y.Z., J.T., W.L.), and Pathology (C.W.), Health Management Center (S.L., X.Z.), and National Clinical Research Center for Geriatric Diseases (B.T., W.L., H.J.), Xiangya Hospital, and School of Computer Science and Engineering (R.Q.), Laboratory of Medical Genetics (B.T., H.J.), and Key Laboratory of Hunan Province in Neurodegenerative Disorders (B.T., H.J.), Central South University, Changsha, Hunan, China; Department of Human Genetics (J.Z.), Emory University School of Medicine, Atlanta, GA; Institute of Chemical Biology and Nanomedicine (ICBN) (Q.C.), Hunan University, Changsha, Hunan, China; Department of Neurology (T.K.), University of Bonn; and German Center for Neurodegenerative Diseases (DZNE) (T.K.), Bonn, Germany.
| |
Collapse
|
9
|
Zhao H, Yang L, Dong Y, Wu ZY. Phenotypic variance in monozygotic twins with SCA3. Mol Genet Genomic Med 2020; 8:e1438. [PMID: 32729243 PMCID: PMC7549591 DOI: 10.1002/mgg3.1438] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2020] [Revised: 07/04/2020] [Accepted: 07/10/2020] [Indexed: 11/06/2022] Open
Abstract
BACKGROUND Spinocerebellar ataxia type 3 (SCA3) is a hereditary neurodegenerative disorder with high clinical heterogeneity. Twin study is valuable to estimate the contributions of gene and/or environment to phenotypic variance. However, SCA3 twins were extremely sparse and rarely reported. METHODS A pair of monozygotic twins with SCA3 was assessed using well-acknowledged scales. Genetic modifiers and methylation levels were determined by Sanger sequencing and pyrosequencing. RESULTS Sharing identical CAG repeat lengths, the twins presented with similar symptoms, whereas, the younger sister had an earlier age at onset of two years. The occurrence time and severity of constipation, blepharospasm and fasciculation were markedly different between the twins. Notable methylation level differences of several CpG sites existed between the twins. CONCLUSIONS It is the first time to report SCA3 monozygotic twin worldwide. The role of epigenetic factors in the phenotype variance deserved more attention. The DNA methylation may influence the phenotypic variance by altering the occurrence time and severity of symptoms, indicating its potential in alleviating the disease.
Collapse
Affiliation(s)
- Hua Zhao
- Department of Neurology and Research Center of Neurology in Second Affiliated Hospital, and Key Laboratory of Medical Neurobiology of Zhejiang Province, Zhejiang University School of Medicine, Hangzhou, China
| | - Lu Yang
- Department of Neurology and Research Center of Neurology in Second Affiliated Hospital, and Key Laboratory of Medical Neurobiology of Zhejiang Province, Zhejiang University School of Medicine, Hangzhou, China
| | - Yi Dong
- Department of Neurology and Research Center of Neurology in Second Affiliated Hospital, and Key Laboratory of Medical Neurobiology of Zhejiang Province, Zhejiang University School of Medicine, Hangzhou, China
| | - Zhi-Ying Wu
- Department of Neurology and Research Center of Neurology in Second Affiliated Hospital, and Key Laboratory of Medical Neurobiology of Zhejiang Province, Zhejiang University School of Medicine, Hangzhou, China
| |
Collapse
|
10
|
Li QF, Cheng H, Yang L, Ma Y, Zhao J, Dong Y, Wu Z. Clinical features and genetic characteristics of homozygous spinocerebellar ataxia type 3. Mol Genet Genomic Med 2020; 8:e1314. [PMID: 32643267 PMCID: PMC7507100 DOI: 10.1002/mgg3.1314] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2020] [Revised: 04/26/2020] [Accepted: 04/28/2020] [Indexed: 12/23/2022] Open
Abstract
Background Homozygous spinocerebellar ataxia type 3 (SCA3) patients, which have an expanded cytosine‐adenine‐guanine (CAG) repeat mutation in both alleles of ATXN3, are extremely rare. Clinical features and genetic characteristics of them were seldom studied. Methods We analyzed seven newly homozygous SCA3 patients from five families and 14 homozygotes reported previously. An additional cohort of 30 heterozygous SCA3 patients were analyzed to compare age at onset (AAO). Results Two out of seven SCA3 homozygotes had the minimum CAG repeats reported so far (55/56 and 56/58). Five patients appeared peripheral neuropathy and two had mild cognitive impairment. The AAO was significantly inversely correlated with both the large and small expanded CAG repeats (r = −.7682, p < .0001). The AAO was significantly earlier in homozygous SCA3 than heterozygous ones (32.81 ± 11.86 versus. 49.90 ± 9.73, p < .0001). In addition, the AAO of our seven homozygotes is elder compared to those reported previously (41.29 years vs. 28.57 years), which may be related to the fewer CAG repeats in our seven patients. Conclusion Gene dosage effect may play an important role in the AAO and severity of disease, and homozygosity for ATXN3 enhances phenotypic severity. Our findings expand clinical features and genetic characteristics of homozygous SCA3 patients.
Collapse
Affiliation(s)
- Quan-Fu Li
- Department of Neurology and Research Center of Neurology in Second Affiliated Hospital, and Key Laboratory of Medical Neurobiology of Zhejiang ProvinceZhejiang University School of MedicineHangzhouChina
| | - Hao‐Ling Cheng
- Department of Neurology and Institute of NeurologyFirst Affiliated Hospital of Fujian Medical UniversityFuzhouChina
| | - Lu Yang
- Department of Neurology and Research Center of Neurology in Second Affiliated Hospital, and Key Laboratory of Medical Neurobiology of Zhejiang ProvinceZhejiang University School of MedicineHangzhouChina
| | - Yin Ma
- Department of Neurology and Research Center of Neurology in Second Affiliated Hospital, and Key Laboratory of Medical Neurobiology of Zhejiang ProvinceZhejiang University School of MedicineHangzhouChina
| | - Jing‐Jing Zhao
- Department of Neurology and Research Center of Neurology in Second Affiliated Hospital, and Key Laboratory of Medical Neurobiology of Zhejiang ProvinceZhejiang University School of MedicineHangzhouChina
| | - Yi Dong
- Department of Neurology and Research Center of Neurology in Second Affiliated Hospital, and Key Laboratory of Medical Neurobiology of Zhejiang ProvinceZhejiang University School of MedicineHangzhouChina
| | - Zhi‐Ying Wu
- Department of Neurology and Research Center of Neurology in Second Affiliated Hospital, and Key Laboratory of Medical Neurobiology of Zhejiang ProvinceZhejiang University School of MedicineHangzhouChina
| |
Collapse
|
11
|
Abstract
The spinocerebellar ataxias (SCAs) comprise more than 40 autosomal dominant neurodegenerative disorders that present principally with progressive ataxia. Within the past few years, studies of pathogenic mechanisms in the SCAs have led to the development of promising therapeutic strategies, especially for SCAs caused by polyglutamine-coding CAG repeats. Nucleotide-based gene-silencing approaches that target the first steps in the pathogenic cascade are one promising approach not only for polyglutamine SCAs but also for the many other SCAs caused by toxic mutant proteins or RNA. For these and other emerging therapeutic strategies, well-coordinated preparation is needed for fruitful clinical trials. To accomplish this goal, investigators from the United States and Europe are now collaborating to share data from their respective SCA cohorts. Increased knowledge of the natural history of SCAs, including of the premanifest and early symptomatic stages of disease, will improve the prospects for success in clinical trials of disease-modifying drugs. In addition, investigators are seeking validated clinical outcome measures that demonstrate responsiveness to changes in SCA populations. Findings suggest that MRI and magnetic resonance spectroscopy biomarkers will provide objective biological readouts of disease activity and progression, but more work is needed to establish disease-specific biomarkers that track target engagement in therapeutic trials. Together, these efforts suggest that the development of successful therapies for one or more SCAs is not far away.
Collapse
|
12
|
Li T, Hou X, Chen Z, Peng Y, Wang P, Xie Y, He L, Yuan H, Peng H, Qiu R, Xia K, Tang B, Jiang H. RNA Expression Profile and Potential Biomarkers in Patients With Spinocerebellar Ataxia Type 3 From Mainland China. Front Genet 2019; 10:566. [PMID: 31249598 PMCID: PMC6584761 DOI: 10.3389/fgene.2019.00566] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2018] [Accepted: 05/29/2019] [Indexed: 12/13/2022] Open
Abstract
Long non-coding RNAs (lncRNAs) play an important role in growth, development, and reproduction and undoubtedly contribute to the pathogenesis and progression of diseases. Emerging evidence suggests the involvement of lncRNAs as regulatory factors in pathological conditions, including some neurodegenerative diseases. Spinocerebellar Ataxia Type 3/Machado–Joseph Disease (SCA3/MJD) has a prominent prevalence in China. Because the role of lncRNAs in SCA3/MJD pathogenesis has not yet been investigated, we conducted a pilot study to investigate the expression profile of lncRNAs by high-throughput sequencing in 12 patients and 12 healthy individuals. The sequencing analysis detected 5,540 known and 2,759 novel lncRNAs. Six lncRNAs were confirmed to be differentially expressed in peripheral blood mononuclear cells between SCA3/MJD patients and healthy individuals and were further validated in cerebellar tissue. Based on these results, NONHSAT022144.2 and NONHSAT165686.1 may be involved in the pathogenesis of SCA3/MJD and may be potential biomarkers for SCA3/MJD. Together with NONHSAT022144.2 and NONHSAT165686.1, the other four novel lncRNAs increase our understanding of lncRNA expression profile.
Collapse
Affiliation(s)
- Tianjiao Li
- Department of Neurology, Xiangya Hospital, Central South University, Changsha, China
| | - Xiaocan Hou
- Department of Neurology, Xiangya Hospital, Central South University, Changsha, China
| | - Zhao Chen
- Department of Neurology, Xiangya Hospital, Central South University, Changsha, China
| | - Yun Peng
- Department of Neurology, Xiangya Hospital, Central South University, Changsha, China
| | - Puzhi Wang
- Department of Neurology, Xiangya Hospital, Central South University, Changsha, China
| | - Yue Xie
- Department of Neurology, Xiangya Hospital, Central South University, Changsha, China
| | - Lang He
- Department of Neurology, Xiangya Hospital, Central South University, Changsha, China
| | - Hongyu Yuan
- Department of Neurology, Xiangya Hospital, Central South University, Changsha, China
| | - Huirong Peng
- Department of Neurology, Xiangya Hospital, Central South University, Changsha, China
| | - Rong Qiu
- School of Information Science and Engineering, Central South University, Changsha, China
| | - Kun Xia
- Medical Genetics Research Center, Central South University, Changsha, China
| | - Beisha Tang
- Department of Neurology, Xiangya Hospital, Central South University, Changsha, China.,Medical Genetics Research Center, Central South University, Changsha, China.,National Clinical Research Center for Geriatric Diseases, Xiangya Hospital, Central South University, Changsha, China.,Key Laboratory of Hunan Province in Neurodegenerative Disorders, Central South University, Changsha, China
| | - Hong Jiang
- Department of Neurology, Xiangya Hospital, Central South University, Changsha, China.,Medical Genetics Research Center, Central South University, Changsha, China.,National Clinical Research Center for Geriatric Diseases, Xiangya Hospital, Central South University, Changsha, China.,Key Laboratory of Hunan Province in Neurodegenerative Disorders, Central South University, Changsha, China
| |
Collapse
|
13
|
de Mattos EP, Kolbe Musskopf M, Bielefeldt Leotti V, Saraiva-Pereira ML, Jardim LB. Genetic risk factors for modulation of age at onset in Machado-Joseph disease/spinocerebellar ataxia type 3: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry 2019; 90:203-210. [PMID: 30337442 DOI: 10.1136/jnnp-2018-319200] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/11/2018] [Revised: 08/24/2018] [Accepted: 09/11/2018] [Indexed: 12/13/2022]
Abstract
OBJECTIVES To perform a systematic review and meta-analysis of genetic risk factors for age at onset (AO) in spinocerebellar ataxia type 3/Machado-Joseph disease (SCA3/MJD). METHODS Two authors independently reviewed reports on the mathematical relationship between CAG length at the expanded ATXN3 allele (CAGexp), and other genetic variants if available, and AO. Publications from January 1994 to September 2017 in English, Portuguese or Spanish and indexed in MEDLINE (PubMed), LILACS or EMBASE were considered. Inclusion criteria were reports with >20 SCA3/MJD carriers with molecular diagnosis performed by capillary electrophoresis. Non-overlapping cohorts were determined on contact with corresponding authors. A detailed analysis protocol was registered at the PROSPERO database prior to data extraction (CRD42017073071). RESULTS Eleven studies were eligible for meta-analysis, comprising 10 individual-participant (n=2099 subjects) and two aggregated data cohorts. On average, CAGexp explained 55.2% (95% CI 50.8 to 59.0; p<0.001) of AO variability. Population-specific factors accounted for 8.3% of AO variance. Cohorts clustered into distinct geographic groups, evidencing significantly earlier AO in non-Portuguese Europeans than in Portuguese/South Brazilians with similar CAGexp lengths. Presence of intermediate ATXN2 alleles (27-33 CAG repeats) significantly correlated with earlier AO. Familial factors accounted for ~10% of AO variability. CAGexp, origin, family effects and CAG length at ATXN2 together explained 73.5% of AO variance. CONCLUSIONS Current evidence supports genetic modulation of AO in SCA3/MJD by CAGexp, ATXN2 and family-specific and population-specific factors. Future studies should take these into account in the search for new genetic modifiers of AO, which could be of therapeutic relevance.
Collapse
Affiliation(s)
- Eduardo Preusser de Mattos
- Programa de Pós-Graduação em Genética e Biologia Molecular, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.,Laboratório de Identificação Genética, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil.,Department of Biomedical Sciences of Cells & Systems, Section of Molecular Cell Biology, University Medical Center Groningen/Groningen University, Groningen, The Netherlands
| | - Maiara Kolbe Musskopf
- Laboratório de Identificação Genética, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil
| | - Vanessa Bielefeldt Leotti
- Departamento de Estatística, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.,Programa de Pós-Graduação em Epidemiologia, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil
| | - Maria Luiza Saraiva-Pereira
- Programa de Pós-Graduação em Genética e Biologia Molecular, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.,Laboratório de Identificação Genética, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil.,Departamento de Bioquímica, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.,Serviço de Genética Médica, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil
| | - Laura Bannach Jardim
- Programa de Pós-Graduação em Genética e Biologia Molecular, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil .,Laboratório de Identificação Genética, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil.,Serviço de Genética Médica, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil.,Departamento de Medicina Interna, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil
| |
Collapse
|
14
|
Chen Z, Sequeiros J, Tang B, Jiang H. Genetic modifiers of age-at-onset in polyglutamine diseases. Ageing Res Rev 2018; 48:99-108. [PMID: 30355507 DOI: 10.1016/j.arr.2018.10.004] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2018] [Revised: 08/03/2018] [Accepted: 10/17/2018] [Indexed: 11/25/2022]
Abstract
Polyglutamine (polyQ) diseases are a group of clinically and genetically heterogeneous neurodegenerative diseases. Expansion size correlates with age-at-onset (AO) and severity, and shows a critical threshold for each polyQ disease. Although an expanded CAG tract is sufficient to trigger disease, not all variation in AO is explained by (CAG)n length, which suggests the contribution of other modifying factors. Methods used to identify genetic modifiers in polyQ diseases have progressed from candidate genes to unbiased genome-wide searches. Inconsistency of results from candidate-genes studies are partly explained by sample size, study design and variable population frequency of "polymorphisms"; a genome-wide search may help elucidating more precise disease mechanisms underlying specific interaction networks. We review known genetic modifiers for polyQ diseases, and discuss developing strategies to find modulation, from common variants to networks disclosing small cumulative effects of key genes and modifying pathways. This may lead to a better understanding of genotype-phenotype correlation and the proposal of new potential targets for therapeutical interventions.
Collapse
|
15
|
Cerebellar lncRNA Expression Profile Analysis of SCA3/MJD Mice. Int J Genomics 2018; 2018:5383517. [PMID: 30046585 PMCID: PMC6036799 DOI: 10.1155/2018/5383517] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2018] [Revised: 04/09/2018] [Accepted: 05/27/2018] [Indexed: 12/27/2022] Open
Abstract
Spinocerebellar ataxia type 3 (SCA3) or Machado-Joseph disease (MJD) is the most common autosomal dominant spinocerebellar ataxia in China with highly clinical heterogeneity, such as progressive cerebellar ataxia, dysarthria, pyramidal signs, external ophthalmoplegia, dysphagia, and distal muscle atrophy. It is caused by the abnormal expansion of CAG repeats in a coding region of ATXN3. However, by focusing on the ATXN3 itself cannot fully explain the heterogeneous clinical features of SCA3/MJD. With the discovery of the increasing number of long noncoding RNAs (lncRNAs) that are believed to be involved in spinocerebellar ataxia type 8 (SCA8) and Huntington disease (HD), we wonder whether the lncRNAs are differentially expressed in the SCA3/MJD patients compared to the nonpatients. As the first step, we used lncRNA-Seq to investigate differential expression of the lncRNAs in the SCA3/MJD mice. Two known lncRNAs, n297609 and n297477, and a novel lncRNA TCONS_00072962 have been identified in SCA3/MJD mice with abnormal expression. The first discovery of the novel lncRNA TCONS_00072962 enriched the lncRNA expression profile in the SCA3/MJD mouse model.
Collapse
|
16
|
Lima M, Raposo M. Towards the Identification of Molecular Biomarkers of Spinocerebellar Ataxia Type 3 (SCA3)/Machado-Joseph Disease (MJD). ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY 2018; 1049:309-319. [PMID: 29427111 DOI: 10.1007/978-3-319-71779-1_16] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
Whereas spinocerebellar ataxia type 3 (SCA3)/Machado-Joseph disease (MJD) remains an untreatable disorder, disease-modifying compounds have begun being tested in the context of clinical trials; their success is dependent on the sensitivity of the methods used to measure subtle therapeutic benefits. Thus, efforts are being made to propose a battery of potential outcome measures, including molecular biomarkers (MBs), which remain to be identified; MBs are particularly pertinent if SCA3 trials are expected to enroll preataxic subjects. Recently, promising candidate MBs of SCA3 have emerged from gene expression studies. In this chapter we provide a synthesis of the cross-sectional and pilot longitudinal studies of blood-based transcriptional biomarkers conducted so far. Other alterations with potential to track the progression of SCA3, such as those involving mitochondrial DNA (mtDNA) are also referred. It is expected that a set of molecular biomarkers can be identified; these will be used in complementarity with clinical and imaging markers to fully track SCA3, from its preataxic phase to the disease stage.
Collapse
Affiliation(s)
- Manuela Lima
- Departamento de Biologia, Faculdade de Ciências e Tecnologia, Universidade dos Açores, Ponta Delgada, Portugal. .,Instituto de Investigação e Inovação em Saúde (I3S), Universidade do Porto, Porto, Portugal. .,Instituto de Biologia Molecular e Celular (IBMC), Universidade do Porto, Porto, Portugal.
| | - Mafalda Raposo
- Departamento de Biologia, Faculdade de Ciências e Tecnologia, Universidade dos Açores, Ponta Delgada, Portugal.,Instituto de Investigação e Inovação em Saúde (I3S), Universidade do Porto, Porto, Portugal.,Instituto de Biologia Molecular e Celular (IBMC), Universidade do Porto, Porto, Portugal
| |
Collapse
|
17
|
Shi Y, Wang C, Huang F, Chen Z, Sun Z, Wang J, Tang B, Ashizawa T, Klockgether T, Jiang H. High Serum GFAP Levels in SCA3/MJD May Not Correlate with Disease Progression. THE CEREBELLUM 2016; 14:677-81. [PMID: 25869927 DOI: 10.1007/s12311-015-0667-7] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
Spinocerebellar ataxia type 3(SCA3), also known as Machado-Joseph disease (MJD), is the most frequent subtype of autosomal dominant inherited spinocerebellar ataxias, which caused by the expansion of CAG repeats in the ATXN3 gene. The number of CAG repeats of the abnormal allele determines the rate of disease progression in patients with SCA3/MJD. Markers to assess the clinical severity, to predict the course of illness and to monitor the efficacy of therapeutic measures, can be clinical, biological, and radiological. Here, we aimed to explore whether the serum glial fibrillary acidic protein (GFAP) may act as a biomarker in SCA3/MJD patients and to evaluate the correlation between some markers with the number of CAG repeats in SCA3/MJD patients. We showed that the serum levels of GFAP were significantly higher in SCA3/MJD patients than in controls. There was a strong positive correlation between the age-adjusted GFAP levels with the number of CAG repeats. Age-adjusted International Cooperative Ataxia Rating Scale (ICARS) scores and Scale for the Assessment and Rating of Ataxia (SARA) scores correlated with the number of CAG repeats. Raw scores and disease duration-adjusted GFAP levels, ICARS scores, and SARA scores were not correlated with the number of CAG repeats. Our results reveal novel evidence for the role of the triplet expansion in SCA3/MJD-associated neuronal damage.
Collapse
Affiliation(s)
- Yuting Shi
- Department of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, People's Republic of China
| | - Chunrong Wang
- Department of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, People's Republic of China
| | - Fengzhen Huang
- Department of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, People's Republic of China.,Department of Neurology and Institute of Translational Medicine, University of South China, The First People's Hospital of Chenzhou, Chenzhou, China
| | - Zhao Chen
- Department of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, People's Republic of China
| | - Zhanfang Sun
- Department of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, People's Republic of China
| | - Junling Wang
- Department of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, People's Republic of China.,Key Laboratory of Hunan Province in Neurodegenerative Disorders, Central South University, Changsha, Hunan, 410008, People's Republic of China
| | - Beisha Tang
- Department of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, People's Republic of China.,Key Laboratory of Hunan Province in Neurodegenerative Disorders, Central South University, Changsha, Hunan, 410008, People's Republic of China.,State Key Lab of Medical Genetics, Central South University, Changsha, Hunan, 410078, People's Republic of China
| | - Tetsuo Ashizawa
- Department of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, People's Republic of China.,Department of Neurology, University of Florida, Gainesville, FL, 32610, USA
| | - Thomas Klockgether
- Department of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, People's Republic of China.,Department of Neurology, University Hospital of Bonn, Bonn, Germany
| | - Hong Jiang
- Department of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, People's Republic of China. .,State Key Lab of Medical Genetics, Central South University, Changsha, Hunan, 410078, People's Republic of China.
| |
Collapse
|
18
|
Bettencourt C, Hensman‐Moss D, Flower M, Wiethoff S, Brice A, Goizet C, Stevanin G, Koutsis G, Karadima G, Panas M, Yescas‐Gómez P, García‐Velázquez LE, Alonso‐Vilatela ME, Lima M, Raposo M, Traynor B, Sweeney M, Wood N, Giunti P, Durr A, Holmans P, Houlden H, Tabrizi SJ, Jones L. DNA repair pathways underlie a common genetic mechanism modulating onset in polyglutamine diseases. Ann Neurol 2016; 79:983-90. [PMID: 27044000 PMCID: PMC4914895 DOI: 10.1002/ana.24656] [Citation(s) in RCA: 146] [Impact Index Per Article: 18.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/19/2015] [Revised: 03/30/2016] [Accepted: 03/30/2016] [Indexed: 12/14/2022]
Abstract
OBJECTIVE The polyglutamine diseases, including Huntington's disease (HD) and multiple spinocerebellar ataxias (SCAs), are among the commonest hereditary neurodegenerative diseases. They are caused by expanded CAG tracts, encoding glutamine, in different genes. Longer CAG repeat tracts are associated with earlier ages at onset, but this does not account for all of the difference, and the existence of additional genetic modifying factors has been suggested in these diseases. A recent genome-wide association study (GWAS) in HD found association between age at onset and genetic variants in DNA repair pathways, and we therefore tested whether the modifying effects of variants in DNA repair genes have wider effects in the polyglutamine diseases. METHODS We assembled an independent cohort of 1,462 subjects with HD and polyglutamine SCAs, and genotyped single-nucleotide polymorphisms (SNPs) selected from the most significant hits in the HD study. RESULTS In the analysis of DNA repair genes as a group, we found the most significant association with age at onset when grouping all polyglutamine diseases (HD+SCAs; p = 1.43 × 10(-5) ). In individual SNP analysis, we found significant associations for rs3512 in FAN1 with HD+SCAs (p = 1.52 × 10(-5) ) and all SCAs (p = 2.22 × 10(-4) ) and rs1805323 in PMS2 with HD+SCAs (p = 3.14 × 10(-5) ), all in the same direction as in the HD GWAS. INTERPRETATION We show that DNA repair genes significantly modify age at onset in HD and SCAs, suggesting a common pathogenic mechanism, which could operate through the observed somatic expansion of repeats that can be modulated by genetic manipulation of DNA repair in disease models. This offers novel therapeutic opportunities in multiple diseases. Ann Neurol 2016;79:983-990.
Collapse
Affiliation(s)
- Conceição Bettencourt
- Department of Molecular Neuroscience, Institute of NeurologyUniversity College LondonLondon WC1N 3BGUnited Kingdom
- Department of Clinical and Experimental Epilepsy, Institute of NeurologyUniversity College LondonLondon WC1N 3BGUnited Kingdom
| | - Davina Hensman‐Moss
- Department of Neurodegenerative Disease, Institute of NeurologyUniversity College LondonLondon WC1N 3BGUnited Kingdom
| | - Michael Flower
- Department of Neurodegenerative Disease, Institute of NeurologyUniversity College LondonLondon WC1N 3BGUnited Kingdom
| | - Sarah Wiethoff
- Department of Molecular Neuroscience, Institute of NeurologyUniversity College LondonLondon WC1N 3BGUnited Kingdom
- Center for Neurology and Hertie Institute for Clinical Brain ResearchEberhard‐Karls‐UniversityTübingenGermany
| | - Alexis Brice
- Inserm U 1127, CNRS UMR 7225, Sorbonne UniversitésUPMC University Paris 06 UMR S 1127, Institut du Cerveau et de la Moelle épinière (ICM)ParisFrance
- APHP, Department of GeneticsUniversity Hospital Pitié‐Salpêtrière75013 ParisFrance
| | - Cyril Goizet
- Université Bordeaux, Laboratoire Maladies Rares: Génétique et MétabolismeINSERM1211BordeauxFrance
- CHU Pellegrin, Service de Génétique Médicale, F‐33000BordeauxFrance
| | - Giovanni Stevanin
- Inserm U 1127, CNRS UMR 7225, Sorbonne UniversitésUPMC University Paris 06 UMR S 1127, Institut du Cerveau et de la Moelle épinière (ICM)ParisFrance
- Ecole Pratique des Hautes Etudes75014 ParisFrance
| | - Georgios Koutsis
- Neurogenetics Unit, 1st Department of NeurologyUniversity of Athens Medical School, Eginition Hospital115 28 AthensGreece
| | - Georgia Karadima
- Neurogenetics Unit, 1st Department of NeurologyUniversity of Athens Medical School, Eginition Hospital115 28 AthensGreece
| | - Marios Panas
- Neurogenetics Unit, 1st Department of NeurologyUniversity of Athens Medical School, Eginition Hospital115 28 AthensGreece
| | - Petra Yescas‐Gómez
- Neurogenetics Department, National Institute of Neurology and Neurosurgery“Manuel Velasco Suárez”Mexico City CP14269Mexico
| | | | - María Elisa Alonso‐Vilatela
- Neurogenetics Department, National Institute of Neurology and Neurosurgery“Manuel Velasco Suárez”Mexico City CP14269Mexico
| | - Manuela Lima
- Department of BiologyUniversity of the Azores9500‐321 Ponta DelgadaPortugal
- Instituto de Investigação e Inovação em SaúdeUniversidade do Porto4150‐180 PortoPortugal
- Institute for Molecular and Cell Biology (IBMC)University of Porto4150‐180 PortoPortugal
| | - Mafalda Raposo
- Department of BiologyUniversity of the Azores9500‐321 Ponta DelgadaPortugal
- Instituto de Investigação e Inovação em SaúdeUniversidade do Porto4150‐180 PortoPortugal
- Institute for Molecular and Cell Biology (IBMC)University of Porto4150‐180 PortoPortugal
| | - Bryan Traynor
- Laboratory of Neurogenetics, National Institute of AgingNIHBethesdaMD 20892, USA
| | - Mary Sweeney
- Neurogenetics Unit, National Hospital for Neurology and NeurosurgeryUniversity College London HospitalsLondon WC1N 3BGUnited Kingdom
| | - Nicholas Wood
- Department of Molecular Neuroscience, Institute of NeurologyUniversity College LondonLondon WC1N 3BGUnited Kingdom
| | - Paola Giunti
- Department of Molecular Neuroscience, Institute of NeurologyUniversity College LondonLondon WC1N 3BGUnited Kingdom
- Ataxia Center, Institute of NeurologyUniversity College LondonLondon WC1N 3BGUnited Kingdom
| | | | - Alexandra Durr
- Inserm U 1127, CNRS UMR 7225, Sorbonne UniversitésUPMC University Paris 06 UMR S 1127, Institut du Cerveau et de la Moelle épinière (ICM)ParisFrance
- APHP, Department of GeneticsUniversity Hospital Pitié‐Salpêtrière75013 ParisFrance
| | - Peter Holmans
- MRC Centre for Neuropsychiatric Genetics and Genomics, Institute of Psychological Medicine and Clinical NeurosciencesCardiff UniversityCardiffCF24 4HQUnited Kingdom
| | - Henry Houlden
- Department of Molecular Neuroscience, Institute of NeurologyUniversity College LondonLondon WC1N 3BGUnited Kingdom
- Neurogenetics Unit, National Hospital for Neurology and NeurosurgeryUniversity College London HospitalsLondon WC1N 3BGUnited Kingdom
| | - Sarah J. Tabrizi
- Department of Neurodegenerative Disease, Institute of NeurologyUniversity College LondonLondon WC1N 3BGUnited Kingdom
| | - Lesley Jones
- MRC Centre for Neuropsychiatric Genetics and Genomics, Institute of Psychological Medicine and Clinical NeurosciencesCardiff UniversityCardiffCF24 4HQUnited Kingdom
| |
Collapse
|
19
|
Raposo M, Bettencourt C, Ramos A, Kazachkova N, Vasconcelos J, Kay T, Bruges-Armas J, Lima M. Promoter Variation and Expression Levels of Inflammatory Genes IL1A, IL1B, IL6 and TNF in Blood of Spinocerebellar Ataxia Type 3 (SCA3) Patients. Neuromolecular Med 2016; 19:41-45. [PMID: 27246313 DOI: 10.1007/s12017-016-8416-8] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2016] [Accepted: 05/25/2016] [Indexed: 12/11/2022]
Abstract
Age at onset in spinocerebellar ataxia type 3 (SCA3/MJD) is incompletely explained by the size of the CAG tract at the ATXN3 gene, implying the existence of genetic modifiers. A role of inflammation in SCA3 has been postulated, involving altered cytokines levels; promoter variants leading to alterations in cytokines expression could influence onset. Using blood from 86 SCA3 patients and 106 controls, this work aimed to analyse promoter variation of four cytokines (IL1A, IL1B, IL6 and TNF) and to investigate the association between variants detected and their transcript levels, evaluated by quantitative PCR. Moreover, the effect of APOE isoforms, known to modulate cytokines, was investigated. Correlations between cytokine variants and onset were tested; the cumulative modifier effects of cytokines and APOE were analysed. Patients carrying the IL6*C allele had a significant earlier onset (4 years in average) than patients carrying the G allele, in agreement with lower mRNA levels produced by IL6*C carriers. The presence of APOE*ɛ2 allele seems to anticipate onset in average 10 years in patients carrying the IL6*C allele; a larger number of patients will be needed to confirm this result. These results highlight the pertinence of conducting further research on the role of cytokines as SCA3 modulators, pointing to the presence of shared mechanisms involving IL6 and APOE.
Collapse
Affiliation(s)
- Mafalda Raposo
- Department of Biology, University of the Azores, Rua Mãe de Deus, Apartado 1422, 9501-801, Ponta Delgada, Azores, Portugal.
- Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal.
- Institute for Molecular and Cell Biology (IBMC), University of Porto, Porto, Portugal.
| | - Conceição Bettencourt
- Department of Clinical and Experimental Epilepsy, UCL Institute of Neurology, London, UK
- Department of Molecular Neuroscience, UCL Institute of Neurology, London, UK
| | - Amanda Ramos
- Department of Biology, University of the Azores, Rua Mãe de Deus, Apartado 1422, 9501-801, Ponta Delgada, Azores, Portugal
- Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal
- Institute for Molecular and Cell Biology (IBMC), University of Porto, Porto, Portugal
| | - Nadiya Kazachkova
- Department of Biology, University of the Azores, Rua Mãe de Deus, Apartado 1422, 9501-801, Ponta Delgada, Azores, Portugal
- Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal
- Institute for Molecular and Cell Biology (IBMC), University of Porto, Porto, Portugal
| | - João Vasconcelos
- Department of Neurology, Hospital do Divino Espírito Santo, Ponta Delgada, Portugal
| | - Teresa Kay
- Department of Clinical Genetics, Hospital of D. Estefania, Lisbon, Portugal
| | - Jácome Bruges-Armas
- Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal
- Institute for Molecular and Cell Biology (IBMC), University of Porto, Porto, Portugal
- SEEBMO, Hospital do Santo Espírito da Ilha Terceira, Angra do Heroísmo, Portugal
| | - Manuela Lima
- Department of Biology, University of the Azores, Rua Mãe de Deus, Apartado 1422, 9501-801, Ponta Delgada, Azores, Portugal
- Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal
- Institute for Molecular and Cell Biology (IBMC), University of Porto, Porto, Portugal
| |
Collapse
|
20
|
Chen S, Gan SR, Cai PP, Ni W, Zhou Q, Dong Y, Wang N, Wu ZY. Mitochondrial NADH Dehydrogenase Subunit 3 Polymorphism Associated with an Earlier Age at Onset in Male Machado-Joseph disease Patients. CNS Neurosci Ther 2015; 22:38-42. [PMID: 26336829 DOI: 10.1111/cns.12443] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2015] [Revised: 07/21/2015] [Accepted: 07/23/2015] [Indexed: 12/19/2022] Open
Abstract
AIMS To investigate the potential effect of six previously reported candidate single nucleotide polymorphisms on age at onset (AAO) among Chinese patients with Machado-Joseph disease (MJD). METHODS Three hundred and twenty-four unrelated molecular-confirmed MJD patients were recruited between January 2006 and December 2014. The screening of candidate polymorphisms was first performed in 173 subjects using the SNaPshot(®) Multiplex System. The mitochondrial NADH dehydrogenase subunit 3 (MT-ND3) polymorphism 10398A>G (rs2853826) was further verified with Sanger sequencing in additional 151 patients. RESULTS An inverse correlation was found between expanded CAG repeat length and AAO. The expanded CAG repeat length can explain 63% of AAO variance. The 10398A polymorphism was significantly associated with a 3-year earlier AAO in male patients with MJD (P = 0.001). Stepwise multiple regressions revealed that the 10398A polymorphism could account for nearly 2% of AAO variance in male patients. CONCLUSION Six candidate SNPs have been screened in Chinese patients with MJD. A remarkable earlier AAO was noted in male Chinese MJD patients with MT-ND3 gene 10398A polymorphism.
Collapse
Affiliation(s)
- Sheng Chen
- Department of Neurology and Research Center of Neurology in Second Affiliated Hospital and the Collaborative Innovation Center for Brain Science, Zhejiang University School of Medicine, Hangzhou, China.,Department of Neurology and Institute of Neurology, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China
| | - Shi-Rui Gan
- Department of Neurology and Institute of Neurology, First Affiliated Hospital, Fujian Medical University, Fuzhou, China
| | - Ping-Ping Cai
- Department of Neurology and Institute of Neurology, First Affiliated Hospital, Fujian Medical University, Fuzhou, China
| | - Wang Ni
- Department of Neurology and Research Center of Neurology in Second Affiliated Hospital and the Collaborative Innovation Center for Brain Science, Zhejiang University School of Medicine, Hangzhou, China
| | - Qi Zhou
- Department of Neurology and Institute of Neurology, First Affiliated Hospital, Fujian Medical University, Fuzhou, China
| | - Yi Dong
- Department of Neurology and Institute of Neurology, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China
| | - Ning Wang
- Department of Neurology and Institute of Neurology, First Affiliated Hospital, Fujian Medical University, Fuzhou, China
| | - Zhi-Ying Wu
- Department of Neurology and Research Center of Neurology in Second Affiliated Hospital and the Collaborative Innovation Center for Brain Science, Zhejiang University School of Medicine, Hangzhou, China
| |
Collapse
|
21
|
Two novel SNPs in ATXN3 3' UTR may decrease age at onset of SCA3/MJD in Chinese patients. PLoS One 2015; 10:e0117488. [PMID: 25689313 PMCID: PMC4331546 DOI: 10.1371/journal.pone.0117488] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2014] [Accepted: 12/24/2014] [Indexed: 02/04/2023] Open
Abstract
Spinocerebellar ataxia type 3 (SCA3), or Machado—Joseph disease (MJD), is an autosomal dominantly-inherited disease that produces progressive problems with movement. It is caused by the expansion of an area of CAG repeats in a coding region of ATXN3. The number of repeats is inversely associated with age at disease onset (AO) and is significantly associated with disease severity; however, the degree of CAG expansion only explains 50 to 70% of variance in AO. We tested two SNPs, rs709930 and rs910369, in the 3’ UTR of ATXN3 gene for association with SCA3/MJD risk and with SCA3/MJD AO in an independent cohort of 170 patients with SCA3/MJD and 200 healthy controls from mainland China. rs709930 genotype frequencies were statistically significantly different between patients and controls (p = 0.001, α = 0.05). SCA3/MJD patients carrying the rs709930 A allele and rs910369 T allele experienced an earlier onset, with a decrease in AO of approximately 2 to 4 years. The two novel SNPs found in this study might be genetic modifiers for AO in SCA3/MJD.
Collapse
|
22
|
Zhou Q, Ni W, Dong Y, Wang N, Gan SR, Wu ZY. The role of apolipoprotein E as a risk factor for an earlier age at onset for Machado-Joseph disease is doubtful. PLoS One 2014; 9:e111356. [PMID: 25369462 PMCID: PMC4219713 DOI: 10.1371/journal.pone.0111356] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2014] [Accepted: 09/23/2014] [Indexed: 12/27/2022] Open
Abstract
Machado-Joseph disease (MJD) is an inherited neurodegenerative disease caused by an expanded CAG repeat in the ATXN3 gene. Although the principal genetic determinant of the age at onset (AAO) is the length of the expanded CAG repeat, the additional genetic contribution of MJD toward the AAO has mostly not yet been clarified. It was recently suggested in two independent studies that apolipoprotein E (APOE) might be associated with AAO variability in MJD patients. To identify the potential modifier effect of APOE polymorphisms on the AAO of MJD patients, 403 patients with MJD (confirmed by molecular tests) from eastern and southeastern China were enrolled in the present study. CAG repeats in the ATXN3 and APOE polymorphisms were genotyped. Data were analyzed using a statistical package. No contribution of APOE polymorphisms to the variance in disease onset was observed using ANCOVA (F = 0.183, P = 0.947). However, significant effects on the AAO of MJD were found for the normal ATXN3 allele and for the interaction of mutant and normal ATXN3 alleles in a multiple linear regression model (P = 0.043 and P = 0.035, respectively). Our study does not support a role for APOE as a genetic modifier of the AAO of MJD. Additionally, our study presents evidence that the normal ATXN3 allele and its interaction with mutant alleles contribute toward AAO variance in MJD patients.
Collapse
Affiliation(s)
- Qi Zhou
- Department of Neurology and Institute of Neurology, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China
- Department of Neurology and Institute of Neurology, First Affiliated Hospital, Fujian Medical University, Fuzhou, Fujian, China
| | - Wang Ni
- Department of Neurology and Institute of Neurology, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China
- Department of Neurology and Institute of Neurology, First Affiliated Hospital, Fujian Medical University, Fuzhou, Fujian, China
| | - Yi Dong
- Department of Neurology and Institute of Neurology, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China
| | - Ning Wang
- Department of Neurology and Institute of Neurology, First Affiliated Hospital, Fujian Medical University, Fuzhou, Fujian, China
| | - Shi-Rui Gan
- Department of Neurology and Institute of Neurology, First Affiliated Hospital, Fujian Medical University, Fuzhou, Fujian, China
- * E-mail: (SRG); (ZYW)
| | - Zhi-Ying Wu
- Department of Neurology and Institute of Neurology, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China
- Department of Neurology and Institute of Neurology, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China
- * E-mail: (SRG); (ZYW)
| |
Collapse
|